US20230414608A1 - Use of atr and chk1 inhibitor compounds - Google Patents
Use of atr and chk1 inhibitor compounds Download PDFInfo
- Publication number
- US20230414608A1 US20230414608A1 US18/343,285 US202318343285A US2023414608A1 US 20230414608 A1 US20230414608 A1 US 20230414608A1 US 202318343285 A US202318343285 A US 202318343285A US 2023414608 A1 US2023414608 A1 US 2023414608A1
- Authority
- US
- United States
- Prior art keywords
- hsv
- atr
- herpesvirus
- compound
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 152
- 239000003112 inhibitor Substances 0.000 title claims description 61
- 101150050673 CHK1 gene Proteins 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 63
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 53
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims abstract description 5
- 101150113535 chek1 gene Proteins 0.000 claims description 78
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 72
- -1 XL844 Chemical compound 0.000 claims description 42
- 230000037361 pathway Effects 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 19
- 230000029812 viral genome replication Effects 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 13
- JZCWLJDSIRUGIN-UHFFFAOYSA-N 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine Chemical compound C1=CC(CNC)=CC=C1C1=NOC(C=2C(=NC=C(N=2)C=2C=CC(=CC=2)S(=O)(=O)C(C)C)N)=C1 JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 claims description 12
- 230000012746 DNA damage checkpoint Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 claims description 6
- SCGCBAAYLFTIJU-CQSZACIVSA-N (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 SCGCBAAYLFTIJU-CQSZACIVSA-N 0.000 claims description 5
- DUIHHZKTCSNTGM-UHFFFAOYSA-N 3-amino-6-(4-methylsulfonylphenyl)-N-phenyl-2-pyrazinecarboxamide Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=CN=C(N)C(C(=O)NC=2C=CC=CC=2)=N1 DUIHHZKTCSNTGM-UHFFFAOYSA-N 0.000 claims description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 5
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims description 5
- MOVBBVMDHIRCTG-LJQANCHMSA-N 4-[(3s)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1h-benzimidazol-2-yl)-6-chloroquinolin-2(1h)-one Chemical compound C([N@](CC1)C2)C[C@@H]1[C@@H]2NC1=C(C=2NC3=CC=CC=C3N=2)C(=O)NC2=CC=C(Cl)C=C21 MOVBBVMDHIRCTG-LJQANCHMSA-N 0.000 claims description 4
- YFNWWNRZJGMDBR-LJQANCHMSA-N PF-00477736 Chemical compound C1=NN(C)C=C1C1=NC2=CC(NC(=O)[C@H](N)C3CCCCC3)=CC3=C2C1=CNNC3=O YFNWWNRZJGMDBR-LJQANCHMSA-N 0.000 claims description 4
- DPLMXAYKJZOTKO-UHFFFAOYSA-N 2-methyl-2-[4-(2-oxo-9-quinolin-3-yl-4h-[1,3]oxazino[5,4-c]quinolin-1-yl)phenyl]propanenitrile Chemical compound C1=CC(C(C)(C#N)C)=CC=C1N1C2=C3C=C(C=4C=C5C=CC=CC5=NC=4)C=CC3=NC=C2COC1=O DPLMXAYKJZOTKO-UHFFFAOYSA-N 0.000 claims description 3
- XEZLBMHDUXSICI-UHFFFAOYSA-N 3-(1-ethylpiperidin-4-yl)oxy-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2,4,6,10,12-hexaene-4-carbonitrile Chemical compound C1CN(CC)CCC1OC1=C(C#N)N=CC2=C1C1=CC=CN=C1N2 XEZLBMHDUXSICI-UHFFFAOYSA-N 0.000 claims description 3
- IAYGCINLNONXHY-LBPRGKRZSA-N 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide Chemical compound NC(=O)NC=1C=C(C=2C=C(F)C=CC=2)SC=1C(=O)N[C@H]1CCCNC1 IAYGCINLNONXHY-LBPRGKRZSA-N 0.000 claims description 3
- IENLGMOXAQMNEH-CYBMUJFWSA-N 3-[(2r)-1-(dimethylamino)propan-2-yl]oxy-5-[[4-methoxy-5-(1-methylpyrazol-4-yl)pyridin-2-yl]amino]pyrazine-2-carbonitrile Chemical compound N=1C=C(C2=CN(C)N=C2)C(OC)=CC=1NC1=CN=C(C#N)C(O[C@H](C)CN(C)C)=N1 IENLGMOXAQMNEH-CYBMUJFWSA-N 0.000 claims description 3
- SRBJWIBAMIKCMV-GFCCVEGCSA-N 5-[(8-chloroisoquinolin-3-yl)amino]-3-[(2r)-1-(dimethylamino)propan-2-yl]oxypyrazine-2-carbonitrile Chemical compound N1=C(C#N)C(O[C@@H](CN(C)C)C)=NC(NC=2N=CC3=C(Cl)C=CC=C3C=2)=C1 SRBJWIBAMIKCMV-GFCCVEGCSA-N 0.000 claims description 3
- DGWXOLHKVGDQLN-UHFFFAOYSA-N 6-cyclohexylmethyloxy-5-nitroso-pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=C(N=O)C(OCC2CCCCC2)=N1 DGWXOLHKVGDQLN-UHFFFAOYSA-N 0.000 claims description 3
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 claims description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 3
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 claims description 3
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950006418 dactolisib Drugs 0.000 claims description 3
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 claims description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 2
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 18
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 112
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 72
- 208000015181 infectious disease Diseases 0.000 description 69
- 241000700584 Simplexvirus Species 0.000 description 62
- 208000035475 disorder Diseases 0.000 description 59
- 239000000203 mixture Substances 0.000 description 47
- 101150027427 ICP4 gene Proteins 0.000 description 36
- 230000004913 activation Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 230000010076 replication Effects 0.000 description 29
- 102000000872 ATM Human genes 0.000 description 28
- 101150090364 ICP0 gene Proteins 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 27
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 26
- 238000010384 proximity ligation assay Methods 0.000 description 25
- 230000003612 virological effect Effects 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 208000037952 HSV-1 infection Diseases 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 22
- 230000027455 binding Effects 0.000 description 20
- 101150026402 DBP gene Proteins 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 210000000805 cytoplasm Anatomy 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 230000005971 DNA damage repair Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 230000003993 interaction Effects 0.000 description 16
- 230000004807 localization Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 15
- 238000010166 immunofluorescence Methods 0.000 description 15
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000009109 Fc receptors Human genes 0.000 description 12
- 108010087819 Fc receptors Proteins 0.000 description 12
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 230000026731 phosphorylation Effects 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 108090000704 Tubulin Proteins 0.000 description 11
- 102000004243 Tubulin Human genes 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 230000004543 DNA replication Effects 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 8
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 8
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 8
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000003879 microtubule-organizing center Anatomy 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000001190 Q-PCR Methods 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000175212 Herpesvirales Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010067152 Oral herpes Diseases 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000008045 co-localization Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 206010023332 keratitis Diseases 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 229960001330 hydroxycarbamide Drugs 0.000 description 5
- 201000006747 infectious mononucleosis Diseases 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000006457 Checkpoint Kinase 2 Human genes 0.000 description 4
- 108010019243 Checkpoint Kinase 2 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 101710130522 mRNA export factor Proteins 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000006648 viral gene expression Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 102100027938 ATR-interacting protein Human genes 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000006373 Bell palsy Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101150013191 E gene Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000001688 Herpes Genitalis Diseases 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 3
- 206010052330 Herpes oesophagitis Diseases 0.000 description 3
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 3
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000007993 Kaposi Varicelliform Eruption Diseases 0.000 description 3
- 101150062031 L gene Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229940123066 Polymerase inhibitor Drugs 0.000 description 3
- 102100026531 Prelamin-A/C Human genes 0.000 description 3
- 239000011542 SDS running buffer Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 3
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 3
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 125000004986 diarylamino group Chemical group 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 206010014197 eczema herpeticum Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 201000004946 genital herpes Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005473 herpetic whitlow Diseases 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000010666 keratoconjunctivitis Diseases 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000009038 pharmacological inhibition Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 208000025889 stromal keratitis Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- NDEXUOWTGYUVGA-LJQANCHMSA-N (2R)-2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide Chemical compound Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O NDEXUOWTGYUVGA-LJQANCHMSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101150065175 Atm gene Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 201000006783 Seckel syndrome Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101150011902 UL52 gene Proteins 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007711 cytoplasmic localization Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- UXGJAOIJSROTTN-UHFFFAOYSA-N 2-[4-(4-chlorophenoxy)phenyl]-3h-benzimidazole-5-carboxamide Chemical compound N1C2=CC(C(=O)N)=CC=C2N=C1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UXGJAOIJSROTTN-UHFFFAOYSA-N 0.000 description 1
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000012827 ATM inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 101100232404 Arabidopsis thaliana IBR3 gene Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 description 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 241000586568 Diaspidiotus perniciosus Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100031381 Fc receptor-like A Human genes 0.000 description 1
- 101710142648 Fc receptor-like A Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000670537 Homo sapiens E3 ubiquitin-protein ligase RNF168 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 108010021101 Lamin Type B Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 101150081841 NBN gene Proteins 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000004909 RNF168 Human genes 0.000 description 1
- 102000004910 RNF8 Human genes 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 1
- 101710178061 Serine/threonine-protein kinase ATR Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000010721 Tubulin Interactions Effects 0.000 description 1
- 101150068034 UL30 gene Proteins 0.000 description 1
- 101150099321 UL42 gene Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000010319 checkpoint response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 101150088049 dna2 gene Proteins 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000052654 human GDNF Human genes 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 101150071637 mre11 gene Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 101150010682 rad50 gene Proteins 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- HSV-1 possesses a large, linear, double stranded genome of approximately 152 kb that encodes approximately 90 unique transcriptional units(1).
- Productive infection is accompanied by a highly regulated sequence of expression including immediate early (IE), early, (E), and late (L).
- the IE genes act as the vanguard of the productive infection to create a favorable cellular milieu for infection and to regulate subsequent E and L gene expression.
- the IE genes encode 5 unique proteins including ICP4, and ICP0, which play important roles in regulating subsequent viral gene expression.
- ICP4 is a multifunctional, DNA binding protein required for all post-IE viral gene expression.
- ICP0 is a non-essential multifunctional E3 ubiquitin ligase that nevertheless has important roles in regulating gene expression and negating host cell defense functions to create a favorable environment for infection.
- Subsequent E and L gene expression includes seven proteins essential for HSV-1 DNA replication: ICP8 (E; ssDNA binding protein), UL9 (E; origin binding protein), a 3 member helicase-primase complex (UL8 (E), UL5 (E), UL52 (E)), and the polymerase UL30 (L) and its processivity factor UL42 (E)(2).
- DNA viruses have a complex relationship with the DNA damage repair (DDR) pathways, which serve to protect the host genome from point mutations, deletions, insertions, and other forms of insult. Most viruses have evolved the means to not only evade DDR surveillance but to use repair pathways to promote their own agenda(3-5).
- DDR pathways defined by their proximal phoshoinositide-3-kinase-related kinases (PIKKs), serve as the principle mediators of the DDR.
- PIKKs proximal phoshoinositide-3-kinase-related kinases
- the ataxia-telangiectasia mutated (ATM) kinase senses and organizes the cellular response to double strand DNA (dsDNA) break repair, while the ATM and Rad3-related (ATR) serine/threonine protein kinase organizes the response to DNA insults such as stalled replication forks and exposure of ssDNA(6).
- ATM and Rad3-related (ATR) serine/threonine protein kinase organizes the response to DNA insults such as stalled replication forks and exposure of ssDNA(6).
- the Chk2 and Chk1 effector kinases act downstream of ATM and ATR, respectively, to help orchestrate and integrate the DDR(7).
- ATM and ATR generally organize repair via homologous recombination (HR) pathways, while DNA-dependent protein kinase (DNA-PK) defines a third arm of the DDR that organizes repair via primarily via nonhomologous end joining (NHEJ)(6).
- HR homologous recombination
- DNA-PK DNA-dependent protein kinase
- ATR like ATM, responds to dsDNA breaks but has broader roles for repairing stalled replication forks and responding to ssDNA at sites of DNA damage (8). Unlike ATM, ATR is essential for survival of proliferating cells (9-11). ATR and ATM have redundant roles in the sensing and repair of DNA, but both are critical for dsDNA break repair and checkpoint response demonstrating they also carry non-redundant functions (10, 12).
- the essential ATR-interacting protein ATRIP delivers ATR to sites of ssDNA coated by RPA.
- HSV-1 infection results in sequestration of ATRIP to virus induced, chaperone-enriched (VICE) domains away from ATR, which localized to nucleoli in both infected and uninfected cells thus preventing ATR activation(26).
- VICE virus induced, chaperone-enriched domains away from ATR, which localized to nucleoli in both infected and uninfected cells thus preventing ATR activation(26).
- ATR and ATRIP antibodies originally employed lacked the appropriate specificity(29).
- Another model asserts that the HSV-1 single stranded DNA binding protein (ICP8) colocalizes to ssDNA with the helicase/primase complex (UL8/UL5/UL52) where they prevent access of the 9-1-1 complex thus blocking ATR activation(28).
- herpesvirus e.g., HSV
- these compounds suffer limitations.
- therapeutic agents that are useful in treating and/or preventing herpesvirus infection and symptoms thereof that are devoid of the limitations of existing agents.
- the subject matter herein provides compounds and methods of using such compounds for treatment of disease and disorders, or symptoms thereof, in a subject.
- the invention provides a method of treating a subject suffering from or susceptible to a herpesvirus infection comprising administering to subject in need thereof a therapeutically effective amount of a compound capable of inhibiting ataxia telangiectasia and Rad3-related protein (ATR)-mediated DNA-damage-checkpoint pathway.
- ATR ataxia telangiectasia and Rad3-related protein
- the compound is capable of binding to or interacting with ATR (e.g., compounds delineated herein).
- the compound is capable of binding to or interacting with checkpoint kinase 1 (Chk1) (e.g., compounds delineated herein).
- the invention provides a method of treating a subject suffering from or susceptible to orofacial herpes, herpes genitalis, herpes keratitis, herpesviral meningitis, herpesviral encephalitis, herpes labialis, herpetic whitlow, herpes gladiatorum, herpetic gingivostomatitis, herpes esophagitis, neonatal herpes simplex, herpetic sycosis, eczema herpeticum, herpetic keratoconjunctivitis, Herpes stromal keratitis, Bell's palsy, schizophrenia or Alzheimer's disease.
- the method includes administering to a subject in need thereof a therapeutically effective amount of a compound delineated herein (e.g., Table 1, antibody), including salt, hydrate or solvate thereof.
- kits for inhibiting one or more components in ATR-mediated DNA-damage-checkpoint pathway assessing the efficacy of a herpesvirus (e.g., HSV) treatment in a subject, monitoring the progress of a subject being treated with an ATR-mediated DNA-damage-checkpoint pathway inhibitor, selecting a subject with a herpesvirus (e.g., HSV) disorder for treatment with ATR-mediated DNA-damage-checkpoint pathway inhibitor, and/or treating a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disorder or symptom.
- a herpesvirus e.g., HSV
- the kit comprises a label or product insert comprising instructions for use of the compound or composition including the compound to treat a herpesvirus (e.g., HSV) infection or a symptom or disorder associated with a herpesvirus (e.g., HSV) infection.
- a herpesvirus e.g., HSV
- a symptom or disorder associated with a herpesvirus e.g., HSV
- the use is administration of the compound or composition to a subject.
- the invention provides a method of treating a symptom or disorder associated with a herpesvirus (e.g., HSV) infection in a subject comprising administering to the subject identified as in need thereof a compound of Table 1 or salt, hydrate or solvate thereof.
- a herpesvirus e.g., HSV
- the symptom or disorder is selected from the group consisting of orofacial herpes, herpes genitalis, herpes keratitis, herpesviral meningitis, herpesviral encephalitis, herpes labialis, herpetic whitlow, herpes gladiatorum, herpetic gingivostomatitis, herpes esophagitis, neonatal herpes simplex, herpetic sycosis, eczema herpeticum, herpetic keratoconjunctivitis, Herpes stromal keratitis, Bell's palsy, schizophrenia and Alzheimer's disease.
- the invention provides a method of inhibiting a herpesvirus (e.g., HSV) in a subject identified as in need of such treatment, comprising administering a compound of Table 1 or salt, hydrate or solvate thereof.
- a herpesvirus e.g., HSV
- the invention also provides a pharmaceutical compositions of the compounds described herein, comprising a compound herein, or a pharmaceutically acceptable ester, salt, or prodrug thereof, together with a pharmaceutically acceptable carrier.
- Panels A-D Localization of DAPI, ICP8, and pChk1S345 in formalin-fixed cells at 3 h.p.i. without Fc receptor block shows artifactual binding of rabbit pChk1 antibody to juxtanuclear position.
- Panels E-H Localization of DAPI, ICP8, and pATRS428 in formalin-fixed cells at 3 h.p.i. without Fc receptor block shows artifactual binding of rabbit pATR antibody to juxtanuclear position.
- Panels I-L Localization of DAPI, ICP4, and pChk1S345 at 4 h.p.i. with 17+HSV-1 in Fc-receptor blocked, unextracted cells.
- M-P Localization of DAPI, ICP8, and pChk1S345 at 3 h.p.i. with 17+HSV-1 in Fc-receptor blocked, pre-extracted cells.
- Panels Q-T Localization of DAPI, ICP8, and pATRS428 at 3 h.p.i. with 17+HSV-1 Fc-receptor blocked, pre-extracted cells.
- FIG. 3 Proximity Ligation Assay (PLA) demonstrates the close association of pATR and pChk1 with ICP0, ICP4 and tubulin at 3 h.p.i of U2OS cells with 17+HSV-1.
- Panel A Bar graph shows the number of positive amplification events per cell for phospho-ATR(S428) or phospho-Chk1(S345) interaction with the indicated proteins. No significant interactions were found in mock-infected cells, while infected cells showed significant pATR and PChk1 interactions with ICP0 and ICP4, but not with ICP8 or ICP27.
- PLA for individual proteins established background levels. Insert micrographs show representative images of the indicated PLA results.
- Panel B Panel B.
- FIG. 4 Inhibition of either ATR or Chk1 kinase activity significantly inhibits HSV-1 replication and virus production.
- Panel A Representative photos of HSV-1 titer plates show the effects of inhibitors on virus production.
- Panel B Quantification of HSV-1 PFU following inhibitor treatment shows that all ATR and Chk1 inhibitors tested, and the control polymerase inhibitor aphidicolin, significantly impact virus production. Inhibitors against ATM, Chk2, or DNA-PK were not found to significantly inhibit virus production.
- Panel C Q-PCR measurements of HSV-1 genome copies show good agreement with the viral titer assays.
- FIG. 6 Inhibition of ATR with VE-822 blocks activation of ATR and Chk-1, while HSV-1 replication is deficient in Seckel patient fibroblasts hypomorphic for ATR.
- FIG. 6 , panel B Western blot demonstrates the ATR inhibitor VE-822 (10 ⁇ M) blocks phosphorylation of Chk1.
- FIG. 6 panel C. Seckel syndrome patient fibroblasts, hypomorphic for ATR, are defective for HSV-1 replication relative to control patient (IBR3) fibroblasts.
- IBR3 control patient
- FIG. 8 Merged images of DAPI, ICP4, and pATR following: FIG. 8 , panel A. Treatment with vehicle (DMSO); FIG. 8 , panel B. treatment with cycloheximide, which completely suppresses pATR labeling and retards replication center formation; FIG. 8 , panel C. treatment with PAA which partially blocks pATR labeling and retards replication center formation.
- DMSO vehicle
- FIG. 8 panel A. Treatment with vehicle (DMSO)
- FIG. 8 panel B. treatment with cycloheximide, which completely suppresses pATR labeling and retards replication center formation
- FIG. 8 panel C. treatment with PAA which partially blocks pATR labeling and retards replication center formation.
- FIG. 9 Rabbit phospho-specific antibodies bind non-specifically if Fc receptor is not blocked.
- the present inventors have now discovered a therapeutic strategy that addresses inhibition of ATR-mediated DNA-damage-checkpoint pathway by targeting ATR pathway interactions. Such interactions are relevant for modulation of HSV disease.
- the present invention also relates, at least in part, to the discovery that the compounds delineated herein demonstrate selective interactions with certain targets (e.g., selective for ATR or Chk1) for HSV infection and/or associated disorder therapy.
- targets e.g., selective for ATR or Chk1
- administration includes routes of introducing the compound of the invention(s) to a subject to perform their intended function.
- routes of administration include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, inhalation, rectal and transdermal.
- the pharmaceutical preparations may be given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred, although topical application may address potential toxicity issues.
- alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
- alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorous atoms.
- a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C 3 -C 30 for branched chain), preferably 26 or fewer, and more preferably 20 or fewer, and still more preferably 4 or fewer.
- preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, 6 or 7 carbons in the ring structure.
- alkyl as used throughout the specification and sentences is intended to include both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoro
- lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six, and still more preferably from one to four carbon atoms in its backbone structure, which may be straight or branched-chain.
- lower alkyl groups include methyl, ethyl, n-propyl, i-propyl, tert-butyl, hexyl, heptyl, octyl and so forth.
- the term “lower alkyl” includes a straight chain alkyl having 4 or fewer carbon atoms in its backbone, e.g., C1-C4 alkyl.
- alkoxyalkyl refers to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
- alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
- the invention contemplates cyano and propargyl groups.
- aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles,” “heteroaryls” or “heteroaromatics.”
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, s
- biological activities of a compound of the invention includes all activities elicited by compound of the inventions in a responsive cell. It includes genomic and non-genomic activities elicited by these compounds.
- Biological composition refers to a composition containing or derived from cells or biopolymers.
- Cell-containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood cell proteins, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of the plasma, a supernatant from any fractionation of the plasma, blood plasma protein fractions, purified or partially purified blood proteins or other components, serum, semen, mammalian colostrum, milk, saliva, placental extracts, a cryoprecipitate, a cryosupernatant, a cell lysate, mammalian cell culture or culture medium, products of fermentation, ascites fluid, proteins induced in blood cells, and products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology).
- Biological compositions can be cell-free.
- a suitable biological composition or biological sample is a red blood cell suspension.
- the blood cell suspension includes mammalian blood cells.
- the blood cells are obtained from a human, a non-human primate, a dog, a cat, a horse, a cow, a goat, a sheep or a pig.
- the blood cell suspension includes red blood cells and/or platelets and/or leukocytes and/or bone marrow cells.
- diastereomers refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
- an effective amount includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., sufficient to treat a disorder delineated herein.
- An effective amount of compound of the invention may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound of the invention to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response.
- An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound of the invention are outweighed by the therapeutically beneficial effects.
- enantiomers refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.”
- haloalkyl is intended to include alkyl groups as defined above that are mono-, di- or polysubstituted by halogen, e.g., fluoromethyl and trifluoromethyl.
- hydroxyl means —OH.
- heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
- homeostasis is art-recognized to mean maintenance of static, or constant, conditions in an internal environment.
- improved biological properties refers to any activity inherent in a compound of the invention that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound of the invention, such as reduced toxicity.
- cell proliferative disorder includes disorders involving the undesired or uncontrolled proliferation of a cell.
- disorders include, but are not limited to, tumors or cancers (e.g., lung (small cell and non-small cell), thyroid, prostate, pancreatic, breast or colon), sarcoma, leukemia, myeloma, lymphoma, or melanoma.
- Optional substitution is also indicated by the phrase “substituted with from 0 to X substituents,” where X is the maximum number of possible substituents.
- Certain optionally substituted groups are substituted with from 0 to 2, 3 or 4 independently selected substituents (i.e., are unsubstituted or substituted with up to the recited maximum number of substituents).
- modulate refers to an increase or decrease, e.g., in the ability of a cell to proliferate in response to exposure to a compound of the invention, e.g., the inhibition of proliferation of at least a sub-population of cells in an animal such that a desired end result is achieved, e.g., a therapeutic result.
- obtaining as in “obtaining a compound” is intended to include purchasing, synthesizing or otherwise acquiring the compound.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- polycyclyl or “polycyclic radical” refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings.
- Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl,
- prodrug or “pro-drug” includes compounds with moieties that can be metabolized in vivo.
- the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs.
- Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19).
- the prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid.
- prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides.
- a prophylactically effective amount of a compound refers to an amount of a compound of the invention any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a disorder delineated herein
- reduced toxicity is intended to include a reduction in any undesired side effect elicited by a compound of the invention when administered in vivo.
- sulfhydryl or “thiol” means —SH.
- subject includes organisms which are capable of suffering from a herpesvirus (e.g., HSV) disorder or who could otherwise benefit from the administration of a compound of the invention of the invention, such as human and non-human animals.
- Preferred humans include human patients suffering from or prone to suffering from a herpesvirus (e.g., HSV) disorder, disorder delineated herein, or associated state, as described herein.
- non-human animals of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.
- HSV disorder is meant to include subjects at risk of developing disorder of HSV, e.g., HSV, i.e., subjects suffering from HSV, subjects having a family or medical history of HSV disorder, and the like.
- systemic administration means the administration of a compound of the invention(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- the invention provides compounds capable of modulating (e.g., inhibiting or stimulating) (directly or indirectly) ATR-binding activity and methods using the compounds thereof.
- the invention provides a compound capable of modulating ATR-mediated protein binding; and pharmaceutically acceptable esters, salts, and prodrugs thereof.
- compounds include antibodies as described herein.
- Certain preferred compounds include compounds specifically delineated herein:
- ATR Pathway Inhibitor Compound Name/ Function Structure VE-821 (ATR Inhibitor) VE-822 (ATR Inhibitor) AZD6738 (ATR Inhibitor) AZ20 (ATR Inhibitor) NVP-BEZ235 (ATR Inhibitor) ETP-46464 (ATR Inhibitor) NU6027 (ATR Inhibitor) Schisandrin B (ATR Inhibitor) CHIR 124 (Chk1 Inhibitor) PF-00477736 (Chk1 Inhibitor) AZD7762 (Chk1 Inhibitor) SCH900776/MK-8776 (Chk1 Inhibitor) IC83/LY2603618 (Chk1 Inhibitor) LY2606368 (Chk1 Inhibitor) GDC-0425 (Chk1 Inhibitor) XL844 (Chk1 Inhibitor) SAR-020106 (Chk1 Inhibitor)
- the invention also relates to the pharmaceutically acceptable salts and esters of the above-mentioned compounds.
- Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., “Chiral Liquid Chromatography,” W. J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers.
- the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like.
- diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid.
- the disclosure provides compositions and methods useful for treating or preventing herpesvirus infection and/or an herpesvirus-associated disease or disorder.
- the disclosure provides compositions and methods useful for treating or preventing a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disease or disorder.
- a herpesvirus e.g., HSV
- HSV- herpesvirus- associated disease or disorder.
- the HSV is HSV-1.
- the HSV is HSV-2.
- the invention provides methods for treating a subject for herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder by administering to the subject an effective amount of a compound capable of disrupting a component of the ATR-mediated DNA-damage-checkpoint pathway.
- the compound does not inhibit ataxia telangiectasia mutated (ATM).
- the compounds of the invention may either directly or indirectly modulate ATR or ATR activity, Chk1 or Chk1 activity, and a subject can be contacted with a compound of the invention to inhibit disease or disorder processes or modulation of the herpesvirus (e.g., HSV) metabolic cascade.
- Contacting cells or administering the compounds of the invention to a subject is one method of treating a cell or a subject suffering from or susceptible to herpesvirus (e.g., HSV) infection or an herpesvirus- (e.g., HSV-) associated disorder.
- the methods of the invention include administering to a subject a therapeutically effective amount of a compound of the invention in combination with another pharmaceutically active compound.
- pharmaceutically active compounds include compounds known to treat viruses and viral disorders, e.g., acyclovir, valaciclovir (valacyclovir), famciclovir, ganciclovir, foscarnet, trifluridine, penciclovir, docosanol, zoster-immune globulin (ZIG), vidarabine, VZV immune globulin, etc.
- Other pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine , Thirteenth Edition, Eds. T. R. Harrison et al.
- the compound of the invention and the pharmaceutically active compound may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).
- herpesvirus e.g., HSV
- Certain of the methods for identification of patients which are at risk of herpesvirus (e.g., HSV) infection and/or disorders which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient.
- a clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination and medical/family history.
- a method of assessing the efficacy of a treatment in a subject includes determining the pre-treatment extent of an herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder by methods well known in the art (e.g., determining markers where the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder is present) and then administering a therapeutically effective amount of an inhibitor of cell proliferation (e.g., those described herein) according to the invention to the subject.
- an herpesvirus e.g., HSV
- HSV- herpesvirus- associated disorder
- the extent of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder is determined again.
- the modulation (e.g., decrease) of the extent or invasiveness of the herpesvirus (e.g., HSV) disorder indicates efficacy of the treatment.
- the extent or invasiveness of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder may be determined periodically throughout treatment.
- obtaining a biological sample from a subject includes obtaining a sample for use in the methods described herein.
- a biological sample is described above.
- methods of inhibiting a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder in a subject include administering an effective amount of a compound of the invention (i.e., a compound described herein) to the subject.
- a compound of the invention i.e., a compound described herein
- the compound includes a antibody as described herein.
- the administration may be by any route of administering known in the pharmaceutical arts.
- the subject may have a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, may be at risk of developing a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, or may need prophylactic treatment prior to anticipated or unanticipated exposure to a conditions capable of increasing susceptibility to an herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, e.g., exposure to carcinogens or to ionizing radiation.
- a herpesvirus e.g., HSV
- the subject may be at risk of herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, may be exhibiting symptoms of an herpesvirus- (e.g., HSV-) associated disorder, may be susceptible to a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder and/or may have been diagnosed with a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder.
- HSV herpesvirus
- HSV- herpesvirus- associated disorder
- the subject may be treated with the compound.
- the subject can be administered therapeutically effective dose or doses of the compound.
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- compositions containing a compound of the invention(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration.
- the compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, more preferably from about 10 percent to about 30 percent.
- compositions include the step of bringing into association a compound of the invention(s) with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compound of the invention(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, so
- the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compound of the invention(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compound of the invention(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
- compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of the invention(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound of the invention(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to compound of the invention(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of the invention(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- the compound of the invention(s) can be alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- a nonaqueous (e.g., fluorocarbon propellant) suspension could be used.
- Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the invention(s) to the body.
- dosage forms can be made by dissolving or dispersing the agent in the proper medium.
- Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of the invention.
- compositions of the invention suitable for parenteral administration comprise one or more compound of the invention(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of compound of the invention(s) in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- biodegradable polymers such as polylactide-polyglycolide.
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- a preferred dose of the compound of the invention for the present invention is the maximum that a patient can tolerate and not develop serious side effects.
- the compound of the invention of the present invention is administered at a concentration of about 0.001 mg to about 100 mg per kilogram of body weight, about 0.001-about 10 mg/kg or about 0.001 mg-about 100 mg/kg of body weight. Ranges intermediate to the above-recited values are also intended to be part of the invention.
- Both pATR and pChk1 were localized to the nucleus within viral replication domains, or associated with their periphery, by 3 h.p.i. Significant levels of pATR and pChk1 were also detected throughout the cytoplasm where they co-localized with ICP4. Proximity ligation assays show that pATR and pChk1 are closely associated with ICP4 and ICP0 in the cytoplasm, presumably in a multi-protein complex, by 3 h.p.i. Multiple, chemically distinct ATR and Chk1 inhibitors inhibit HSV-1 replication and virion production, while inhibitors of ATM, Chk2, and DNA-PK are ineffective. Together our data strongly suggest that HSV-1 activates the ATR pathway at early stages of infection, and that ATR and Chk1 kinase activities play important roles in HSV-1 replication fitness.
- HSV-1 viral strains were used in this study: 17syn+KOS/M, McIntyre and McKrae, KD6.
- U2OS cells were maintained in McCoy's 5A media (Corning, catalog no. 10-050-CV) supplemented with 10% FBS and 1 ⁇ Penicillin Streptomycin Glutamine (PSG; Gibco catalog no. 10378).
- Vero, and human fetal lung (HFL) cells were maintained in DMEM (Corning, catalog no. 10-013-CV) with 10% FBS and 1 ⁇ PSG).
- Rabbit skin cells 60 were maintained in MEM (Gibco, catalog no. 11700077) plus 5% bovine serum and 1 ⁇ PSG.
- rabbit skin cells were plated at 150,000 cells/well of 24-well plates and the following day infected with 10-fold serial dilutions of virus harvested from antiviral experiments. Cells were incubated for 48 h, stained with 1% crystal violet solution, and plaques counted from three separate wells for each experimental sample.
- Q-PCR was conducted using 20 ng input DNA, TaqMan® Fast Universal PCR 2 ⁇ Master Mix (Applied Biosystems, catalog no.
- cells were incubated with primary antibodies (same antibodies and dilutions as described for IF) for 1 h at RT, washed 3 ⁇ 5′ with PBS containing 1% BSA and 0.1% NP-40 (WDB) and incubated with the diluted PLA probes (diluted in WDB) per manufacturer's recommendation for 1 h at 37° C.
- Cells were washed 2 ⁇ 5′ with Wash Buffer A (from kit) and Detection was performed by incubating cells with the Ligation reaction mix for 30′ at 37° C. Cells were washed 2 ⁇ 2′ with Wash Buffer A and Amplification was performed by incubating cells with Polymerase reaction mix for 100 min at 37° C.
- the Western blots examined a 6 h. time course of infection. Total ATM, ATR and Chk1 levels, detected with pan-specific antibodies, did not change over the course of the experiments ( FIGS. 1 , panels A and B).
- the MTOC is also the site of formation of the human cytomegalovirus (CMV) “assembly compartment,” which was previously shown to especially bind rabbit IgG antibodies(62) due to the presence of CMV encoded Fc receptor-like protein(63) causing spurious results.
- CMV human cytomegalovirus
- Example 2 Activated ATR and Chk1 Interact with ICP4, ICP0, and Tubulin, but not with ICP8 and ICP27
- the specific ATR kinase VE-822 was next used to examine ATR/Chk1 activation ( FIG. 6 ).
- VE-822 blocked ATR activation as observed by immunofluorescence ( FIG. 6 , panel A), while Chk1 activation was also blocked as observed in Western blots ( FIG. 6 , panel B).
- this series of experiments also showed that ATR inhibition by VE-822 blocked expression of ICP4 ( FIG. 6 , Panel A) and ICP8 (data not shown) suggesting ATR kinase activity is required for viral fitness and viral DNA replication.
- fibroblasts derived from a Seckel syndrome patient
- ATR hypomorphic mutation resulting in impaired ATR function(28).
- HSV-1 replication was depressed in the ATR-deficient cells relative to the normal patient fibroblasts throughout the 48 h. time course ( FIG. 6 , panel C).
- U2OS cells infected with 17+HSV-1 were treated with one of four chemically distinct ATR inhibitors (VE-822, VE-821, AZD-6738, and AZ20), or 2 unique Chk1 inhibitors (Chir124 and PF477736), or inhibitors of ATM, Chk2, or DNA-PK ( FIG. 4 ).
- ATR inhibitors VE-822, VE-821, AZD-6738, and AZ20
- 2 unique Chk1 inhibitors Chir124 and PF477736
- ICP0, ICP4, and ICP27 are IE phosphoproteins with the greatest effects upon HSV-1 gene expression and growth(1, 19, 35, 36). All three proteins have consensus Chk1 phosphorylation sites but no ATR sites.
- ICP8 an IE ssDNA binding protein that organizes the earliest stages of HSV-1 replication(37-39), has 3 ATR consensus sites and one Chk1 site.
- One ATR site exists within the C-terminal 60 amino acid region that is required for ICP8 filament assembly and cooperative ssDNA binding(40, 41), immediately adjacent to a short sequence apparently required for ICP8 self-interactions(42). Numerous other HSV-1 proteins with central roles in viral DNA replication also possess multiple ATR and Chk1 consensus sites.
- Viral DNA replication is required for activation of the ATR pathway following infection.
- Incoming viral genomes at the earliest stages of HSV-1 infection are linear DNAs with ends, nicks, and gaps that might be expected of to activate DDR pathways (43-45).
- Vero cells activate ATR following infection with the replication-incompetent KD6 mutant. No evidence of Chk1 activation was noted in Vero cells although Chk1 was clearly activated following KD6 infection of permissive Vero cell line K5, and activation in these cells was blocked by the protein synthesis inhibitor cycloheximide.
- ICP4 and ICP0 have long been recognized as important for activation of E and L gene expression. ICP0 was first identified based upon its ability to cooperate with ICP4 to promote viral mRNA synthesis (50, 51). Studies of the ability of ICP0-viruses to replicate at low versus high MOIs led to the concept that ICP0 inactivates a repressor of HSV gene expression (52-54). Other studies have shown that the two proteins are able to physically interact (55, 56).
- ATR and Chk1 are activated shortly after infection of multiple cell lines by HSV-1 strains 17+, KOS, McKrae, or McIntyre. The pathway appears to be activated by events of early gene expression.
- pATR and pChk1 are found in the nucleus within viral replication centers or on their periphery. Both pATR and pChk1 are also found in the cytoplasm during early stages of infection where they directly interact with ICP4 and ICP0.
- the specific ATR inhibitor VE-822 blocks activation of both ATR and Chk1 during infection. It also blocks maturation of replication centers during infection by blocking expression of both ICP4 and ICP8.
- Viral replication and production is significantly attenuated by treatment with multiple, chemically-distinct inhibitors of ATR and Chk1, but not inhibitors of ATM or Chk2.
- HSV-1 replication is also impaired in Seckel patient fibroblasts that are hypomorphic ATR.
- ATR cytoplasmic localization and function of activated ATR and Chk1.
- ATR regulates hundreds of down-stream targets, including anti-apoptotic mitochondrial elements, and its distribution in the cytoplasm following DNA damage is well documented (65).
- Chk1 has nuclear export sequences and is mobilized to control cytoplasmic targets following DNA damage (66).
- Precedence also exists for exploitation of these DDR elements in the cytoplasm by viruses.
- Vaccinia a poxvirus that replicates exclusively in the cytoplasm, activates cytoplasmic ATR, ATM, and DNA-PK, and utilizes ATR and Chk1 to promote viral genome replication (67, 68).
- Incoming viral genomes at the earliest stages of HSV-1 infection are linear DNAs with ends, nicks, and gaps that might be expected of to activate DDR pathways (43-45).
- the complete suppression of ATR and Chk1 activation by cycloheximide indicates that new protein synthesis is required for ATR activation, and suggests that incoming viral genomes are not the cause of activation.
- the ATR pathway is also activated at early times during acute infection in the presence of PAA, a viral polymerase inhibitor, we hypothesize that early gene expression rather than viral DNA replication is an important initial event resulting in ATR activation.
- the partial suppression of ATR activation by PAA suggests that viral DNA replication may contribute to the amplification of the ATR signaling cascade.
- ATR and Chk1 are found within the nucleus associated with the periphery of developing viral replication centers after 3 h. of HSV-1 infection. Pharmacological inhibition of ATR dramatically halts viral replication center growth and maturation. The data clearly demonstrate that ATR and Chk1 are robustly activated, and that ATR and Chk1 kinase activities are required for early HSV-1 fitness and replication. But the data are inconsistent with previous reports that concluded ATR is not activated during HSV-1 infection (17, 22), and that ATR is purposely inactivated by HSV-1 infection (23, 24). To the best of our knowledge, pATR or pChk1 localization by immunological techniques using phospho-specific antibodies were not pursued in these studies.
- ATR and Chk1 inhibitors show potent antiviral effects against HSV-1 when used at concentrations that are reported to significantly inhibit their target protein and spare closely related kinases such as ATM and Chk2. These findings show that ATR and Chk1 kinase activities are utilized by HSV-1 to promote important aspects of viral gene expression and replication. Consistent with this is the observation that ATR inhibition: 1) inhibits expression of early genes (such as ICP4 and ICP8); 2) blocks the maturation of viral nuclear replication centers; and 3) suppresses viral growth as measured by Q-PCR or and plaque assay. While the mechanism by which ATR pathway activation enhances HSV infection is currently not clear, we hypothesize it is through down-stream effects on viral and/or host processes.
- ICP4 and ICP0 act to re-direct ATR and Chk1 phosphorylation away from host targets to HSV replication proteins. It should will be useful to identify those targets of ATR and Chk1 phosphorylation that are required to maintain early viral gene expression, replication, and fitness. Importantly, the understanding that ATR and Chk1 are activated by HSV-1 to promote viral fitness will enable future studies designed to understand this important process and to perhaps design new therapeutic approaches.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. provisional application No. 62/393,166, filed Sep. 12, 2016, the entire contents of which are incorporated by reference herein.
- This invention was made with government support under Grant No. AI097376, awarded by the National Institutes of Health. The government has certain rights in the invention.
- Infection by the common human pathogen herpes simplex virus (HSV) establishes life long, recurrent disease with the primary infection usually occurring within oral or genital epithelia, and latency established in the sensory ganglia innervating these tissues.
- HSV-1 possesses a large, linear, double stranded genome of approximately 152 kb that encodes approximately 90 unique transcriptional units(1). Productive infection is accompanied by a highly regulated sequence of expression including immediate early (IE), early, (E), and late (L). The IE genes act as the vanguard of the productive infection to create a favorable cellular milieu for infection and to regulate subsequent E and L gene expression. The IE genes encode 5 unique proteins including ICP4, and ICP0, which play important roles in regulating subsequent viral gene expression. ICP4 is a multifunctional, DNA binding protein required for all post-IE viral gene expression. ICP0 is a non-essential multifunctional E3 ubiquitin ligase that nevertheless has important roles in regulating gene expression and negating host cell defense functions to create a favorable environment for infection. Subsequent E and L gene expression includes seven proteins essential for HSV-1 DNA replication: ICP8 (E; ssDNA binding protein), UL9 (E; origin binding protein), a 3 member helicase-primase complex (UL8 (E), UL5 (E), UL52 (E)), and the polymerase UL30 (L) and its processivity factor UL42 (E)(2).
- DNA viruses have a complex relationship with the DNA damage repair (DDR) pathways, which serve to protect the host genome from point mutations, deletions, insertions, and other forms of insult. Most viruses have evolved the means to not only evade DDR surveillance but to use repair pathways to promote their own agenda(3-5). Three DDR pathways, defined by their proximal phoshoinositide-3-kinase-related kinases (PIKKs), serve as the principle mediators of the DDR. The ataxia-telangiectasia mutated (ATM) kinase senses and organizes the cellular response to double strand DNA (dsDNA) break repair, while the ATM and Rad3-related (ATR) serine/threonine protein kinase organizes the response to DNA insults such as stalled replication forks and exposure of ssDNA(6). The Chk2 and Chk1 effector kinases act downstream of ATM and ATR, respectively, to help orchestrate and integrate the DDR(7). ATM and ATR generally organize repair via homologous recombination (HR) pathways, while DNA-dependent protein kinase (DNA-PK) defines a third arm of the DDR that organizes repair via primarily via nonhomologous end joining (NHEJ)(6).
- ATR, like ATM, responds to dsDNA breaks but has broader roles for repairing stalled replication forks and responding to ssDNA at sites of DNA damage (8). Unlike ATM, ATR is essential for survival of proliferating cells (9-11). ATR and ATM have redundant roles in the sensing and repair of DNA, but both are critical for dsDNA break repair and checkpoint response demonstrating they also carry non-redundant functions (10, 12). The essential ATR-interacting protein ATRIP delivers ATR to sites of ssDNA coated by RPA. These sites include stalled replication forks as well as dsDNA breaks where resection of the DNA ends occurs due to the nuclease activity of the dsDNA break-sensing Mre11-Rad50-Nbs1 (MRN) complex and its associated nucleases including CtIP, Exo1, and Dna2(13-15).
- HSV-1 has significant connections with all three of these DDR pathways(16). ICP0 is recognized to block DNA-PK function by targeting its catalytic subunit for proteosomal degradation(17-19). ATM, on the other hand is activated following HSV-1 infection(20, 21). Activation of ATM accompanies the recruitment of numerous HR elements to viral replication centers including members of the dsDNA break-sensing MRN complex (Mre11, Rad50, and Nbs1) and RAD51(20-22), However, ICP0 targeting of the histone ubiquitin ligases RNF8 and RNF168 hinders actual DNA repair and results in increased HSV-1 fitness(23). Thus it appears that HSV-1 successfully attracts and maintains numerous HR elements in replication centers in order to promote virus replication while minimizing the antiviral properties of the pathway. Many DNA viruses, large and small, employ this strategy to promote their replication(4, 24).
- Multiple reports assert that ATR is not activated following HSV-1 infection. The negative data include lack of phosphorylation of well-known ATR substrates including Chk1 (21, 25) and RPA(22, 26). It has also been reported that inhibition of the HSV-1 polymerase with PAA results in RPA phosphorylation, presumably by ATR(22, 27). Other reports have asserted that ATR is inactivated by HSV-1 based upon the observations that inhibition of the HSV-1 infection appears to block hyperphosphorylation of RPA and Chk1 induced by either hydroxyurea or UV irradiation(28). Several studies have attempted to mechanistically explain why ATR would not be activated following infection. For example, it was reported that HSV-1 infection results in sequestration of ATRIP to virus induced, chaperone-enriched (VICE) domains away from ATR, which localized to nucleoli in both infected and uninfected cells thus preventing ATR activation(26). However, this model was abandoned with the realization that the ATR and ATRIP antibodies originally employed lacked the appropriate specificity(29). Another model asserts that the HSV-1 single stranded DNA binding protein (ICP8) colocalizes to ssDNA with the helicase/primase complex (UL8/UL5/UL52) where they prevent access of the 9-1-1 complex thus blocking ATR activation(28).
- In spite of these observations there remain conflicting findings to suggest that ATR might have a role to play in early stages of HSV-1 infection. For example, a recent report found that ATR-deficient fibroblasts are defective in their ability to support HSV-1 replication(30). Results described herein now establish that HSV-1 infection, specifically viral early gene transcription, activates the ATR pathway. Both ATR and Chk1 activities are found to be required for robust viral replication since multiple, chemically distinct ATR and Chk1 inhibitors significantly attenuate virus production. Together these results provide strong evidence that HSV-1 activates the ATR pathway redirecting the kinase activity of its two principal members to alternative substrates that promote virus production.
- While to date certain compounds are being considered for therapeutic use in herpesvirus (e.g., HSV) treatment and prevention, these compounds suffer limitations. As such, there is a need for therapeutic agents that are useful in treating and/or preventing herpesvirus infection and symptoms thereof that are devoid of the limitations of existing agents.
- The subject matter herein provides compounds and methods of using such compounds for treatment of disease and disorders, or symptoms thereof, in a subject.
- In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a herpesvirus infection comprising administering to subject in need thereof a therapeutically effective amount of a compound capable of inhibiting ataxia telangiectasia and Rad3-related protein (ATR)-mediated DNA-damage-checkpoint pathway. In one embodiment, the compound is capable of binding to or interacting with ATR (e.g., compounds delineated herein). In another embodiment, the compound is capable of binding to or interacting with checkpoint kinase 1 (Chk1) (e.g., compounds delineated herein).
- In one aspect, the invention provides a method of inhibiting herpesvirus (e.g., HSV) replication in a subject. The method can comprise inhibition of ATR. The method can comprise inhibition of activated ATR. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound delineated herein (e.g., Table 1, antibody) including salt, hydrate or solvate thereof.
- In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound delineated herein (e.g., Table 1, antibody) including salt, hydrate or solvate thereof.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to orofacial herpes, herpes genitalis, herpes keratitis, herpesviral meningitis, herpesviral encephalitis, herpes labialis, herpetic whitlow, herpes gladiatorum, herpetic gingivostomatitis, herpes esophagitis, neonatal herpes simplex, herpetic sycosis, eczema herpeticum, herpetic keratoconjunctivitis, Herpes stromal keratitis, Bell's palsy, schizophrenia or Alzheimer's disease. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound delineated herein (e.g., Table 1, antibody), including salt, hydrate or solvate thereof.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to an HSV-associated disorder or symptom thereof, comprising administering to the subject an effective amount of a compound (e.g., those delineated herein) such that the subject is treated.
- In another aspect, the invention provides a packaged composition including a therapeutically effective amount of an ATR-mediated DNA-damage-checkpoint pathway inhibitor and a pharmaceutically acceptable carrier or diluent. The composition may be formulated for treating a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection and/or disorder or symptom thereof, and packaged with instructions to treat a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection and/or disorder or symptom thereof.
- In one aspect, the invention provides a kit for treating or preventing a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disorder or symptom in a subject is provided and includes a compound herein, pharmaceutically acceptable esters, salts, and prodrugs thereof, and instructions for use. In further aspects, the invention provides kits for inhibiting one or more components in ATR-mediated DNA-damage-checkpoint pathway, assessing the efficacy of a herpesvirus (e.g., HSV) treatment in a subject, monitoring the progress of a subject being treated with an ATR-mediated DNA-damage-checkpoint pathway inhibitor, selecting a subject with a herpesvirus (e.g., HSV) disorder for treatment with ATR-mediated DNA-damage-checkpoint pathway inhibitor, and/or treating a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disorder or symptom. In certain embodiments, the invention provides: a kit for treating or preventing a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disorder or symptom in a subject, the kit comprising a compound capable of modulating (e.g., inhibiting) ATR activity or ATR binding interactions. In certain embodiments, the invention provides: a kit for treating a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disorder or symptom in a subject, the kit comprising a compound capable of modulating (e.g., inhibiting) Chk1 activity or Chk1 binding interactions. In certain embodiments, the kit comprises a label or product insert comprising instructions for use of the compound or composition including the compound to treat a herpesvirus (e.g., HSV) infection or a symptom or disorder associated with a herpesvirus (e.g., HSV) infection. In some embodiments the use is administration of the compound or composition to a subject.
- In one aspect, the invention provides a method of treating or preventing a herpesvirus (e.g., HSV) infection in a subject comprising administering to the subject identified as in need thereof a compound selected from Table 1 or salt, hydrate or solvate thereof. In some embodiments, the subject is administered an additional therapeutic agent. In some embodiments, the compound selected from Table 1 and the additional therapeutic agent are administered simultaneously. In some embodiments, the compound selected from Table 1 and the additional therapeutic agent are administered sequentially. In some embodiments, the HSV is HSV-1 or HSV-2.
- In some embodiments, the compound selected from Table 1 or salt, hydrate or solvate thereof inhibits ATR-mediated DNA-damage-checkpoint pathway. In some embodiments, the compound selected from Table 1 or salt, hydrate or solvate thereof is an inhibitor of ATR. In some embodiments, the inhibitor of ATR is selected from the group consisting of VE-821, VE-822, AZD6738, AZ20, NVP-BEZ235, ETP-46464, NU6027, and Schisandrin B.
- In some embodiments, the compound selected from Table 1 or salt, hydrate or solvate thereof is an inhibitor of Chk1. In some embodiments, the inhibitor of Chk1 is selected from the group consisting of CHIR 124, PF-00477736, AZD7762, SCH900776/MK-8776, IC83/LY2603618, LY2606368, GDC-0425, XL844, SAR-020106, and CCT-244747. In some embodiments, the compound selected from Table 1 or salt, hydrate or solvate thereof does not inhibit ATM.
- In one aspect, the invention provides a method of treating a symptom or disorder associated with a herpesvirus (e.g., HSV) infection in a subject comprising administering to the subject identified as in need thereof a compound of Table 1 or salt, hydrate or solvate thereof. In some embodiments, the symptom or disorder is selected from the group consisting of orofacial herpes, herpes genitalis, herpes keratitis, herpesviral meningitis, herpesviral encephalitis, herpes labialis, herpetic whitlow, herpes gladiatorum, herpetic gingivostomatitis, herpes esophagitis, neonatal herpes simplex, herpetic sycosis, eczema herpeticum, herpetic keratoconjunctivitis, Herpes stromal keratitis, Bell's palsy, schizophrenia and Alzheimer's disease.
- In one aspect, the invention provides a method for reducing herpesvirus (e.g., HSV) viral replication comprising contacting a cell with an ATR-mediated DNA-damage-checkpoint pathway inhibitor compound.
- In one aspect, the invention provides a method of inhibiting a herpesvirus (e.g., HSV) in a subject identified as in need of such treatment, comprising administering a compound of Table 1 or salt, hydrate or solvate thereof.
- In other aspects, the herpesvirus described herein can be HSV-1, HSV-2, Varicella zoster virus (which causes chicken-pox and shingles), Epstein-Barr virus (which causes mononucleosis),
human herpesvirus 6, human herpesvirus 7, Kaposi's sarcoma-associated herpesvirus, Pseudorabies virus (cause of Aujeszky's disease in pigs), gaHV-2 (cause of Marek's disease in chickens), BHV-1 (cause of bovine infectious rhinotracheitis and pustular vulvovaginitis in cattle), and EHV-1 (cause of rhinopneumonitis in horses). - The invention also provides a pharmaceutical compositions of the compounds described herein, comprising a compound herein, or a pharmaceutically acceptable ester, salt, or prodrug thereof, together with a pharmaceutically acceptable carrier.
- The invention also provides methods for designing, evaluating and identifying compounds which bind to the aforementioned binding pockets. Other embodiments of the invention are disclosed infra.
- The present invention is further described below with reference to the following non-limiting examples and with reference to the following figures, in which:
-
FIG. 1 . Western blots demonstrating phosphorylation of pChk1S345 and pATRS428 over time following infection. Panel A. U2OS (top) or Vero (bottom) cells were infected with 17+HSV-1 (MOI=10) and prepared for Western blotting at the indicated h.p.i. with the indicated antibodies recognizing pChk1(S345) or Chk1(Pan). Chk1 activation is first detected at 3 h.p.i. in both cell types. Panel B. U2OS cells were infected with 17+HSV-1 (MOI=10) and prepared for Western blotting at the indicated h.p.i. with the indicated antibodies recognizing ATM(S1981), ATM(Pan), ATR(S428), and ATR(Pan). ATM activation is first detected at the end of the pre-incubation period (0 h.p.i.) while evidence of ATR phosphorylation is first seen at 3 h.p.i. -
FIG. 2 . Localization of pATR and pChk1 following 17+HSV-1 infection (MOI=10) of U2OS cells. Panels A-D: Localization of DAPI, ICP8, and pChk1S345 in formalin-fixed cells at 3 h.p.i. without Fc receptor block shows artifactual binding of rabbit pChk1 antibody to juxtanuclear position. Panels E-H: Localization of DAPI, ICP8, and pATRS428 in formalin-fixed cells at 3 h.p.i. without Fc receptor block shows artifactual binding of rabbit pATR antibody to juxtanuclear position. Panels I-L: Localization of DAPI, ICP4, and pChk1S345 at 4 h.p.i. with 17+HSV-1 in Fc-receptor blocked, unextracted cells. M-P: Localization of DAPI, ICP8, and pChk1S345 at 3 h.p.i. with 17+HSV-1 in Fc-receptor blocked, pre-extracted cells. Panels Q-T: Localization of DAPI, ICP8, and pATRS428 at 3 h.p.i. with 17+HSV-1 Fc-receptor blocked, pre-extracted cells. Bottom row of micrographs shows higher magnification merged images of insert boxes in Panels D, H, L & P. Scale bars=20 microns in Panels A-P, and 10 microns in bottom two rows. -
FIG. 3 . Proximity Ligation Assay (PLA) demonstrates the close association of pATR and pChk1 with ICP0, ICP4 and tubulin at 3 h.p.i of U2OS cells with 17+HSV-1. Panel A. Bar graph shows the number of positive amplification events per cell for phospho-ATR(S428) or phospho-Chk1(S345) interaction with the indicated proteins. No significant interactions were found in mock-infected cells, while infected cells showed significant pATR and PChk1 interactions with ICP0 and ICP4, but not with ICP8 or ICP27. PLA for individual proteins established background levels. Insert micrographs show representative images of the indicated PLA results. Panel B. Bar graph shows the number of positive amplification events per cell for phospho-ATR(S428) or phospho-Chk1(S345) interaction with tubulin. PLA for tubulin alone was negative. Insert micrographs show representative images of the indicated PLA results. Scale bars=10 microns. -
FIG. 4 . Inhibition of either ATR or Chk1 kinase activity significantly inhibits HSV-1 replication and virus production. Panel A, Representative photos of HSV-1 titer plates show the effects of inhibitors on virus production. Panel B. Quantification of HSV-1 PFU following inhibitor treatment shows that all ATR and Chk1 inhibitors tested, and the control polymerase inhibitor aphidicolin, significantly impact virus production. Inhibitors against ATM, Chk2, or DNA-PK were not found to significantly inhibit virus production. Asterisk (*) indicates statistical significance (Student's t-test): p<0.005 in all cases except for PF477736 where p=0.006. Panel C. Q-PCR measurements of HSV-1 genome copies show good agreement with the viral titer assays. -
FIG. 5 . Activated Chk1 and ATR are found in the nucleus and also in the cytoplasm where they sometimes co-localize with ICP4.FIG. 5 , panel A. Merged images of DAPI, pChk1 or pATR, and Lamin A/C labelled cells. Activated Chk1 is found within the nucleus in hydroxyurea (HU)-treated cells. Cells infected with 17+ show pChk1 and pATR distribution as defined by co-localization with Lamin A/C. Arrows point to pATR or pChk1 outside nucleus. Scale bars=10 microns.FIG. 5 , panel B. Both pATR (5 h.p.i. with 17+HSV-1; MOI=10) and pChk1 (5 h.p.i. with 17+HSV-1; MOI=10) are found in the nucleus adjacent to and associated with replication centers defined by ICP4 expression, and also in the cytoplasm where they sometimes co-localize with ICP4 (arrows). Scale bars=10 microns.FIG. 5 , panel C. Western blots for fractionated samples for the indicated proteins. Shown are two separately conducted fractionations conducted at 6 h.p.i. with 17+HSV-1 (MOI=10). -
FIG. 6 . Inhibition of ATR with VE-822 blocks activation of ATR and Chk-1, while HSV-1 replication is deficient in Seckel patient fibroblasts hypomorphic for ATR.FIG. 6 , panel A. Low magnification immunofluorescence images of ICP4 and pATR at 5 h.p.i. infection with 17+HSV-1 (MOI=10) and treatment of cells with vehicle (DMSO) or ATR inhibitor VE-822 (10 μM). Scale bars=50 microns.FIG. 6 , panel B. Western blot demonstrates the ATR inhibitor VE-822 (10 μM) blocks phosphorylation of Chk1.FIG. 6 , panel C. Seckel syndrome patient fibroblasts, hypomorphic for ATR, are defective for HSV-1 replication relative to control patient (IBR3) fibroblasts. -
FIG. 7 . Immunofluorescence time course after blocking non-specific binding with Fc receptor blocking reagent shows activation of ATR and Chk1 following 17+HSV-1 infection (MOI=10), which is consistent with Western blot time course (FIG. 1 ). -
FIG. 8 . Merged images of DAPI, ICP4, and pATR following:FIG. 8 , panel A. Treatment with vehicle (DMSO);FIG. 8 , panel B. treatment with cycloheximide, which completely suppresses pATR labeling and retards replication center formation;FIG. 8 , panel C. treatment with PAA which partially blocks pATR labeling and retards replication center formation. -
FIG. 9 . Rabbit phospho-specific antibodies bind non-specifically if Fc receptor is not blocked. Initial experiments found that rabbit phospho-specific antibodies bound in the vicinity of the microtubule-organizing center (MTOC) following infection by 17+(MOI=10) of U2OS cells, and microtubule inhibition results in their cytoplasmic dispersal. A-D: Colocalization of DAPI, tubulin, and pChk1S345 binding following 17+HSV-1 (MOI=10) at 2 h.p.i. Note that pChk1 labelling was not expected at 2 h.p.i. The box in D shows higher magnification image of pChk1 antibody binding around MTOC. Scale bars=20 microns. E-H: Higher magnification images of localization of DAPI, tubulin, and rabbit pChk1S345 antibody binding with no Fc receptor block. Scale bars=10 microns. I-L: Localization of DAPI, ICP8, and pChk1S345 antibody binding following HSV-1 infection (MOI=10) of U2OS cells and colchicine disruption of microtubules demonstrates that pChk1 antibody binding is dispersed throughout the cytoplasm. Scale bars=20 microns. L-O: Localization of DAPI, tubulin, and pChk1S345 antibody binding following HSV-1 infection (MOI=10) of U2OS cells and colchicine disruption of microtubules shows dispersal of pChk1 antibody binding from the juxtanuclear position. Scale bars=20 microns. - The present inventors have now discovered a therapeutic strategy that addresses inhibition of ATR-mediated DNA-damage-checkpoint pathway by targeting ATR pathway interactions. Such interactions are relevant for modulation of HSV disease.
- The present invention also relates, at least in part, to the discovery that the compounds delineated herein demonstrate selective interactions with certain targets (e.g., selective for ATR or Chk1) for HSV infection and/or associated disorder therapy.
- Before further description of the present invention, and in order that the invention may be more readily understood, certain terms are first defined and collected here for convenience.
- The term “administration” or “administering” includes routes of introducing the compound of the invention(s) to a subject to perform their intended function. Examples of routes of administration that may be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, inhalation, rectal and transdermal. The pharmaceutical preparations may be given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred, although topical application may address potential toxicity issues. The injection can be bolus or can be continuous infusion. Depending on the route of administration, the compound of the invention can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function. The compound of the invention can be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both. The compound of the invention can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent. Furthermore, the compound of the invention can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.
- The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorous atoms. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), preferably 26 or fewer, and more preferably 20 or fewer, and still more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, 6 or 7 carbons in the ring structure.
- Moreover, the term alkyl as used throughout the specification and sentences is intended to include both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl” also includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six, and still more preferably from one to four carbon atoms in its backbone structure, which may be straight or branched-chain. Examples of lower alkyl groups include methyl, ethyl, n-propyl, i-propyl, tert-butyl, hexyl, heptyl, octyl and so forth. In preferred embodiment, the term “lower alkyl” includes a straight chain alkyl having 4 or fewer carbon atoms in its backbone, e.g., C1-C4 alkyl.
- The terms “alkoxyalkyl,” “polyaminoalkyl” and “thioalkoxyalkyl” refer to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
- The terms “alkenyl” and “alkynyl” refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively. For example, the invention contemplates cyano and propargyl groups.
- The term “aryl” as used herein, refers to the radical of aryl groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles,” “heteroaryls” or “heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).
- The term “associating with” refers to a condition of proximity between a chemical entity or compound, or portions thereof, and a binding pocket or binding site on a protein. The association may be non-covalent (wherein the juxtaposition is energetically favored by hydrogen bonding or van der Waals or electrostatic interactions) or it may be covalent.
- The term “binding pocket”, as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity or compound.
- The language “biological activities” of a compound of the invention includes all activities elicited by compound of the inventions in a responsive cell. It includes genomic and non-genomic activities elicited by these compounds.
- “Biological composition” or “biological sample” refers to a composition containing or derived from cells or biopolymers. Cell-containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood cell proteins, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of the plasma, a supernatant from any fractionation of the plasma, blood plasma protein fractions, purified or partially purified blood proteins or other components, serum, semen, mammalian colostrum, milk, saliva, placental extracts, a cryoprecipitate, a cryosupernatant, a cell lysate, mammalian cell culture or culture medium, products of fermentation, ascites fluid, proteins induced in blood cells, and products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology). Biological compositions can be cell-free. In a preferred embodiment, a suitable biological composition or biological sample is a red blood cell suspension. In some embodiments, the blood cell suspension includes mammalian blood cells. Preferably, the blood cells are obtained from a human, a non-human primate, a dog, a cat, a horse, a cow, a goat, a sheep or a pig. In preferred embodiments, the blood cell suspension includes red blood cells and/or platelets and/or leukocytes and/or bone marrow cells.
- The term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- The term “diastereomers” refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
- The term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., sufficient to treat a disorder delineated herein. An effective amount of compound of the invention may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound of the invention to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound of the invention are outweighed by the therapeutically beneficial effects.
- A therapeutically effective amount of compound of the invention (i.e., an effective dosage) may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound of the invention in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound of the invention used for treatment may increase or decrease over the course of a particular treatment.
- The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.”
- The term “haloalkyl” is intended to include alkyl groups as defined above that are mono-, di- or polysubstituted by halogen, e.g., fluoromethyl and trifluoromethyl.
- The term “halogen” designates —F, —Cl, —Br or —I.
- The term “hydroxyl” means —OH.
- The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
- The term “homeostasis” is art-recognized to mean maintenance of static, or constant, conditions in an internal environment.
- The language “improved biological properties” refers to any activity inherent in a compound of the invention that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound of the invention, such as reduced toxicity.
- The term “cell proliferative disorder” includes disorders involving the undesired or uncontrolled proliferation of a cell. Examples of such disorders include, but are not limited to, tumors or cancers (e.g., lung (small cell and non-small cell), thyroid, prostate, pancreatic, breast or colon), sarcoma, leukemia, myeloma, lymphoma, or melanoma.
- The term “optionally substituted” is intended to encompass groups that are unsubstituted or are substituted by other than hydrogen at one or more available positions, typically 1, 2, 3, 4 or 5 positions, by one or more suitable groups (which may be the same or different). Such optional substituents include, for example, hydroxy, halogen, cyano, nitro, C1-C8alkyl, C2-C8 alkenyl, C2-C8alkynyl, C1-C8alkoxy, C2-C8alkyl ether, C3-C8alkanone, C1-C8alkylthio, amino, mono- or di-(C1-C8alkyl)amino, haloC1-C8alkyl, haloC1-C8alkoxy, C1-C8alkanoyl, C2-C8alkanoyloxy, C1-C8alkoxycarbonyl, —COOH, —CONH2, mono- or di-(C1-C8alkyl)aminocarbonyl, —SO2NH2, and/or mono or di(C1-C8alkyl)sulfonamido, as well as carbocyclic and heterocyclic groups. Optional substitution is also indicated by the phrase “substituted with from 0 to X substituents,” where X is the maximum number of possible substituents. Certain optionally substituted groups are substituted with from 0 to 2, 3 or 4 independently selected substituents (i.e., are unsubstituted or substituted with up to the recited maximum number of substituents).
- The term “isomers” or “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- The term “modulate” refers to an increase or decrease, e.g., in the ability of a cell to proliferate in response to exposure to a compound of the invention, e.g., the inhibition of proliferation of at least a sub-population of cells in an animal such that a desired end result is achieved, e.g., a therapeutic result.
- The term “obtaining” as in “obtaining a compound” is intended to include purchasing, synthesizing or otherwise acquiring the compound.
- The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- The terms “polycyclyl” or “polycyclic radical” refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- The term “prodrug” or “pro-drug” includes compounds with moieties that can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionoic acid esters and acyl esters. Prodrugs which are converted to active forms through other mechanisms in vivo are also included.
- The language “a prophylactically effective amount” of a compound refers to an amount of a compound of the invention any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a disorder delineated herein
- The language “reduced toxicity” is intended to include a reduction in any undesired side effect elicited by a compound of the invention when administered in vivo.
- The term “sulfhydryl” or “thiol” means —SH.
- The term “subject” includes organisms which are capable of suffering from a herpesvirus (e.g., HSV) disorder or who could otherwise benefit from the administration of a compound of the invention of the invention, such as human and non-human animals. Preferred humans include human patients suffering from or prone to suffering from a herpesvirus (e.g., HSV) disorder, disorder delineated herein, or associated state, as described herein. The term “non-human animals” of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.
- The term “susceptible to a HSV disorder” is meant to include subjects at risk of developing disorder of HSV, e.g., HSV, i.e., subjects suffering from HSV, subjects having a family or medical history of HSV disorder, and the like.
- The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound of the invention(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- The language “therapeutically effective amount” of a compound of the invention of the invention refers to an amount of an agent which is effective, upon single or multiple dose in ameliorating a herpesvirus (e.g., HSV) disorder, or in prolonging the survivability of the patient with such a herpesvirus (e.g., HSV) disorder beyond that expected in the absence of such treatment.
- With respect to the nomenclature of a chiral center, terms “d” and “1” configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate, epimer and enantiomer will be used in their normal context to describe the stereochemistry of preparations.
- In one aspect, the invention provides compounds capable of modulating (e.g., inhibiting or stimulating) (directly or indirectly) ATR-binding activity and methods using the compounds thereof.
- In one embodiment, the invention provides a compound capable of modulating ATR-mediated protein binding; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In some embodiments, compounds include antibodies as described herein.
- Certain preferred compounds include compounds specifically delineated herein:
-
TABLE 1 ATR Pathway Inhibitor Compounds: Compound Name/ Function Structure VE-821 (ATR Inhibitor) VE-822 (ATR Inhibitor) AZD6738 (ATR Inhibitor) AZ20 (ATR Inhibitor) NVP-BEZ235 (ATR Inhibitor) ETP-46464 (ATR Inhibitor) NU6027 (ATR Inhibitor) Schisandrin B (ATR Inhibitor) CHIR 124 (Chk1 Inhibitor) PF-00477736 (Chk1 Inhibitor) AZD7762 (Chk1 Inhibitor) SCH900776/MK-8776 (Chk1 Inhibitor) IC83/LY2603618 (Chk1 Inhibitor) LY2606368 (Chk1 Inhibitor) GDC-0425 (Chk1 Inhibitor) XL844 (Chk1 Inhibitor) SAR-020106 (Chk1 Inhibitor) CCT-244747 (Chk1 Inhibitor) - The invention also relates to the pharmaceutically acceptable salts and esters of the above-mentioned compounds.
- Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., “Chiral Liquid Chromatography,” W. J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
- In certain aspects, the disclosure provides compositions and methods useful for treating or preventing herpesvirus infection and/or an herpesvirus-associated disease or disorder. Among other aspects, the disclosure provides compositions and methods useful for treating or preventing a herpesvirus (e.g., HSV) infection and/or a herpesvirus- (e.g., HSV-) associated disease or disorder. In some embodiments, the HSV is HSV-1. In some embodiments, the HSV is HSV-2.
- In one embodiment, the invention provides methods for treating a subject for herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder by administering to the subject an effective amount of a compound capable of disrupting a component of the ATR-mediated DNA-damage-checkpoint pathway. In some embodiments, the compound does not inhibit ataxia telangiectasia mutated (ATM).
- In this embodiment, the compounds of the invention may either directly or indirectly modulate ATR or ATR activity, Chk1 or Chk1 activity, and a subject can be contacted with a compound of the invention to inhibit disease or disorder processes or modulation of the herpesvirus (e.g., HSV) metabolic cascade. Contacting cells or administering the compounds of the invention to a subject is one method of treating a cell or a subject suffering from or susceptible to herpesvirus (e.g., HSV) infection or an herpesvirus- (e.g., HSV-) associated disorder.
- In some embodiments, methods and compositions provided herein are useful for treating one or more diseases or disorders associated with herpesvirus (e.g., HSV). For example, in some embodiments, the one or more diseases or disorders can include orofacial herpes, herpes genitalis, herpes keratitis, herpesviral meningitis, herpesviral encephalitis, herpes labialis, herpetic whitlow, herpes gladiatorum, herpetic gingivostomatitis, herpes esophagitis, neonatal herpes simplex, herpetic sycosis, eczema herpeticum, herpetic keratoconjunctivitis, Herpes stromal keratitis, Bell's palsy, schizophrenia and Alzheimer's disease.
- In certain embodiments, the methods of the invention include administering to a subject a therapeutically effective amount of a compound of the invention in combination with another pharmaceutically active compound. Examples of pharmaceutically active compounds include compounds known to treat viruses and viral disorders, e.g., acyclovir, valaciclovir (valacyclovir), famciclovir, ganciclovir, foscarnet, trifluridine, penciclovir, docosanol, zoster-immune globulin (ZIG), vidarabine, VZV immune globulin, etc. Other pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T. R. Harrison et al. McGraw-Hill N.Y., NY; and the Physicians Desk Reference 50th Edition 1997, Oradell New Jersey, Medical Economics Co., the complete contents of which are expressly incorporated herein by reference. The compound of the invention and the pharmaceutically active compound may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).
- Treatment can be initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. A therapeutically effective amount and a prophylactically effective anti-proliferative amount of a compound of the invention of the invention is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day.
- Compounds determined to be effective for the prevention or treatment of disease or disorders in animals, e.g., dogs, chickens, and rodents, may also be useful in treatment of tumors in humans. Those skilled in the art of treating tumors in humans will know, based upon the data obtained in animal studies, the dosage and route of administration of the compound to humans. In general, the dosage and route of administration in humans is expected to be similar to that in animals.
- The identification of those patients who are in need of prophylactic treatment for herpesvirus (e.g., HSV) infection and/or disorders is well within the ability and knowledge of one skilled in the art. Certain of the methods for identification of patients which are at risk of herpesvirus (e.g., HSV) infection and/or disorders which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient. A clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination and medical/family history.
- A method of assessing the efficacy of a treatment in a subject includes determining the pre-treatment extent of an herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder by methods well known in the art (e.g., determining markers where the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder is present) and then administering a therapeutically effective amount of an inhibitor of cell proliferation (e.g., those described herein) according to the invention to the subject. After an appropriate period of time after the administration of the compound (e.g., 1 day, 1 week, 2 weeks, one month, six months), the extent of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder is determined again. The modulation (e.g., decrease) of the extent or invasiveness of the herpesvirus (e.g., HSV) disorder indicates efficacy of the treatment. The extent or invasiveness of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder may be determined periodically throughout treatment. For example, the extent or invasiveness of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder may be checked every few hours, days or weeks to assess the further efficacy of the treatment. A decrease in extent or invasiveness of the herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder indicates that the treatment is efficacious. The method described may be used to screen or select patients that may benefit from treatment with an inhibitor of ATR-mediated DNA-damage-checkpoint pathway.
- As used herein, “obtaining a biological sample from a subject,” includes obtaining a sample for use in the methods described herein. A biological sample is described above.
- In another aspect, a compound of the invention is packaged in a therapeutically effective amount with a pharmaceutically acceptable carrier or diluent. The composition may be formulated for treating a subject suffering from or susceptible to a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, and packaged with instructions to treat a subject suffering from or susceptible to herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder.
- In another aspect, methods of inhibiting a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder in a subject include administering an effective amount of a compound of the invention (i.e., a compound described herein) to the subject. In some embodiments, the compound includes a antibody as described herein. The administration may be by any route of administering known in the pharmaceutical arts. The subject may have a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, may be at risk of developing a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, or may need prophylactic treatment prior to anticipated or unanticipated exposure to a conditions capable of increasing susceptibility to an herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, e.g., exposure to carcinogens or to ionizing radiation.
- The subject may be at risk of herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, may be exhibiting symptoms of an herpesvirus- (e.g., HSV-) associated disorder, may be susceptible to a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder and/or may have been diagnosed with a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder.
- If the modulation of the status indicates that the subject may have a favorable clinical response to the treatment, the subject may be treated with the compound. For example, the subject can be administered therapeutically effective dose or doses of the compound.
- Kits of the invention include kits for treating a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder in a subject. The kit may include a compound of the invention, for example, a compound described herein, pharmaceutically acceptable esters, salts, and prodrugs thereof, and instructions for use. The instructions for use may include information on dosage, method of delivery, storage of the kit, etc. The kits may also include, reagents, for example, test compounds, buffers, media (e.g., cell growth media), cells, etc. Test compounds may include known compounds or newly discovered compounds, for example, combinatorial libraries of compounds. One or more of the kit of the invention may be packaged together, for example, a kit for assessing the efficacy of an treatment for a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder may be packaged with a kit for monitoring the progress of a subject being treated for a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder according to the invention.
- The present methods can be performed on cells in culture, e.g. in vitro or ex vivo, or on cells present in an animal subject, e.g., in vivo. Compounds of the inventions can be initially tested in vitro using primary cultures of proliferating cells, e.g., transformed cells, tumor cell lines, and the like.
- The present method can be performed on cells in culture, e.g. in vitro or ex vivo, or on cells present in an animal subject, e.g., in vivo. Compound of the invention can be initially tested in vitro using cells or other mammalian or non-mammalian animal models. Alternatively, the effects of compound of the invention can be characterized in vivo using animals models.
- The invention also provides a pharmaceutical composition, comprising an effective amount of a compound and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treat a herpesvirus (e.g., HSV) infection and/or herpesvirus- (e.g., HSV-) associated disorder, as described previously. The pharmaceutical composition can be for human or veterinary use.
- In an embodiment, the compound of the invention is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- In certain embodiments, these pharmaceutical compositions are suitable for topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- The phrase “pharmaceutically acceptable” refers to those compound of the inventions of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- The phrase “pharmaceutically-acceptable carrier” includes pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier is “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- Compositions containing a compound of the invention(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, more preferably from about 10 percent to about 30 percent.
- Methods of preparing these compositions include the step of bringing into association a compound of the invention(s) with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the invention(s) as an active ingredient. A compound may also be administered as a bolus, electuary or paste.
- In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
- The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compound of the invention(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- In addition to inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions, in addition to the active compound of the invention(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compound of the invention(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
- Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of the invention(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound of the invention(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- The ointments, pastes, creams and gels may contain, in addition to compound of the invention(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of the invention(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- The compound of the invention(s) can be alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
- Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the invention(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
- Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the invention.
- Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more compound of the invention(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of compound of the invention(s) in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- When the compound of the invention(s) are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.
- Regardless of the route of administration selected, the compound of the invention(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. An exemplary dose range is from 0.1 to 10 mg per day.
- A preferred dose of the compound of the invention for the present invention is the maximum that a patient can tolerate and not develop serious side effects. Preferably, the compound of the invention of the present invention is administered at a concentration of about 0.001 mg to about 100 mg per kilogram of body weight, about 0.001-about 10 mg/kg or about 0.001 mg-about 100 mg/kg of body weight. Ranges intermediate to the above-recited values are also intended to be part of the invention.
- The invention is further illustrated by the following examples which are intended to illustrate but not limit the scope of the invention.
- The ATM and Rad3-related (ATR) protein kinase, and its downstream effector Chk1, are key sensors and organizers of the DNA damage response (DDR) to a variety of insults. Previous studies of Herpes Simplex Virus 1 (HSV-1) have failed to show evidence for activation of the ATR pathway. Using antibodies recognizing pChk1(S345), a site phosphorylated by ATR, we observed intense immunolabeling using multiple HSV-1 strains and cell types. Western blots confirmed that both ATR and Chk1 were activated by 3 h.p.i., and that ATR-specific inhibitors blocked activation and maturation of viral replication centers. Both pATR and pChk1 were localized to the nucleus within viral replication domains, or associated with their periphery, by 3 h.p.i. Significant levels of pATR and pChk1 were also detected throughout the cytoplasm where they co-localized with ICP4. Proximity ligation assays show that pATR and pChk1 are closely associated with ICP4 and ICP0 in the cytoplasm, presumably in a multi-protein complex, by 3 h.p.i. Multiple, chemically distinct ATR and Chk1 inhibitors inhibit HSV-1 replication and virion production, while inhibitors of ATM, Chk2, and DNA-PK are ineffective. Together our data strongly suggest that HSV-1 activates the ATR pathway at early stages of infection, and that ATR and Chk1 kinase activities play important roles in HSV-1 replication fitness.
- Viruses have evolved complex associations with cellular DNA damage response (DDR) pathways, which sense troublesome DNA structures formed during infection. The first evidence for activation of a key DDR pathway by HSV-1 is presented. Both pATR and its downstream target pChk1 are activated robustly by 3 h.p.i. Both proteins are found in the nucleus associated with viral replication compartments, and in the cytoplasm associated with viral proteins. We demonstrate that both ATR and Chk1 kinase activities are important for viral replication. The findings suggest that HSV-1 activates ATR and Chk1 during early stages of infection, and utilizes the kinases to promote its own replication. The observation may be exploitable for antiviral approaches.
- Viruses and Cell lines: Several HSV-1 viral strains were used in this study: 17syn+KOS/M, McIntyre and McKrae, KD6. U2OS cells were maintained in McCoy's 5A media (Corning, catalog no. 10-050-CV) supplemented with 10% FBS and 1× Penicillin Streptomycin Glutamine (PSG; Gibco catalog no. 10378). Vero, and human fetal lung (HFL) cells were maintained in DMEM (Corning, catalog no. 10-013-CV) with 10% FBS and 1×PSG). Rabbit skin cells (60) were maintained in MEM (Gibco, catalog no. 11700077) plus 5% bovine serum and 1×PSG. Seckel patient (ATR-) (61) and normal patient (1BR3) fibroblast cell lines immortalized with hTert (kindly provided by Peggy Jeggo, University of Sussex) were maintained in Eagle's MEM supplemented with 10% FBS and 1×PSG using a 1:2 split ratio. Cells were plated in 24-well dishes at a density of 1.5×105 cells per well and the following day infected with 17syn+ at an MOI=0.01. Following incubation at the indicated time-points, cells were harvested and DNA isolated using DNAzol following the manufacturer's recommendation. 20 ng of total DNA was analyzed for HSV-1 genomes by Q-PCR (see below). The LUHMES neuronal cell line was purchased from ATCC (catalog no. CRL-2927) and cultured on poly-1-ornithine hydrobromide (Sigma, catalog no. P3655)+fibronectin (Sigma, catalog no. F2006) coated flasks, plates and coverslips in proliferation media (DMEM-F12, ATCC, catalog no. 30-2006; 1×N-2 Supplement, ThermoFisher Sci., catalog no. 17502048; 40 ng/mL recombinant human FGF-basic, Peprotech, catalog no. 100-18B-100UG) as described in Scholz et al. Experiments were conducted on LUHMES following at least five days of differentiation in proliferation media supplemented with tetracycline hydrochloride at 1 ug/mL (Sigma catalog no. T7660), N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt at 1 mM final (Sigma, catalog no. D0627) and recombinant human GDNF at 2 ng/mL (R&D Systems, catalog no. 212-GD-010).
- Inhibitors: The following ATR inhibitors were purchased from Selleckchem and used at 10 μM final: VE-822 (catalog no. S7102 Batch No. 1), VE-821 (catalog no. S8007), AZD6738 (catalog no. S7693), and AZ20 (catalog no. S7050). Chk1 inhibitors were purchased from Axon Medchem and used at 250 nM final concentration (CHIR 124, catalog no. Axon 1636 and
PF 477736, catalog no. Axon 1379). Other chemical inhibitors and their final concentrations described in this study are: Chk2 inhibitor II hydrate (5 μM, Sigma, catalog no. C3742), ATM inhibitor KU55933 (10 μM, Tocris, catalog no. 3544), DNA-PK inhibitor NU7441 (1 μM, Tocris, catalog no. 3712), and aphidicolin (4 μM, Sigma, catalog no. A0781). - Antibodies: The following antibodies were used in this study: Phospho-Chk1 (Ser345) (133D3) Rabbit mAb (Cell Signaling, catalog no. 2348); Phospho-Chk1 (Ser345) Rabbit polyclonal (ThermoFisher Sci., catalog no. PA5-34625); Chk1 (2G1D5) mouse mAb (Cell Signaling, catalog no. 2360); α-HSV-1 ICP4 hybridoma; Tubulin (α+β) mouse mAb (abcam, catalog no. ab44928); α-HSV-1 ICP8 mouse mAb 11E2 (abcam, catalog no. ab20194), α-HSV-1 ICP0 mouse mAb 5H7 (abcam, catalog no. ab6513); Phospho-ATR (Ser428) Rabbit polyclonal Ab (Cell Signaling, catalog no. 2853); Phospho-ATR (Ser428) Rabbit polyclonal Ab (ThermoFisher Sci., catalog no. 720107); ATR (H-300) rabbit polyclonal Ab (Santa Cruz, catalog no. sc-28901); Phospho-ATM (Ser1981) Rabbit mAb EP1890Y (abcam, catalog no. ab81292); ATM mouse mAb2C1(1A1) (abcam, catalog no. ab78); Lamin A/C (4C11) mouse mAb (Cell Signaling, catalog no. 4777).
- Antiviral Assays, HSV-1 Titering and Q-PCR: Cells were plated at 5×105 cells per well in 6-well plates and the following morning incubated with inhibitors. Following 1 h pre-incubation with inhibitors, cells were infected with HSV-1 at an MOI=0.1 in a volume of 200 uL for 1 h, viral inoculum removed, and cells overlaid with media containing fresh inhibitors, and cultured for 48 h. Following 48 h, cells and supernatant were harvested by scraping, separated into two Eppendorf tubes, and centrifuged at 10,000×g for 40 min. The cell pellet from one tube was used for extraction of DNA (DNazol according to manufacturer's recommendation, ThermoFisher Sci. catalog no. 10503027) and the second pellet was re-suspended in 200 uL serum-free MEM, freeze-thawed 3×, and virus titered on rabbit skin cells. For HSV-1 titering, rabbit skin cells were plated at 150,000 cells/well of 24-well plates and the following day infected with 10-fold serial dilutions of virus harvested from antiviral experiments. Cells were incubated for 48 h, stained with 1% crystal violet solution, and plaques counted from three separate wells for each experimental sample. Q-PCR was conducted using 20 ng input DNA, TaqMan® Fast Universal PCR 2× Master Mix (Applied Biosystems, catalog no. 4352041) along with TaqMan probes and target-specific primers (Applied Biosystems, Assays by Design part no. 4331348) against HSV-1 polymerase. Samples were run on a StepOnePlus Real-Time PCR System (Applied Biosystems) using fast cycling: denaturation at 95° C. for 20 sec followed by 40 cycles at 95° C. for 1 sec and 60° C. for 20 sec. Additional experimental compounds were also tested as follows: (57) Cyclohexamide (Sigma, catalog no. C7698) or DMSO vehicle was added to the overlay media at 50 ug/mL and the infection allowed to proceed for 5 h. (2) For replication inhibition, phosphonoacetic acid (PAA) was added at time of virus adsorption and included in overlay media at 400 ug/mL for 5 h. (3) A final [3 mM] hydroxyurea was added at the time of cell plating and incubated for 18 h.
- Western Blotting: 5×105 cells were plated on 6-well plates and infected the following day with 17syn+(MOI=10). At the indicated times, cells were lysed in buffer containing 1% NP-40, 150 mM sodium chloride, 20 mM Tris-HCL pH 8.0, 2 mM EDTA, and 5% glycerol supplemented with phosphatase and protease inhibitor cocktails (Roche, PhosSTOP tablets; catalog no. 04906837001; ThermoFisherSci., Halt Protease Inhibitor Cocktail, catalog no. 1862209). For SDS-PAGE, 20 ug of protein was mixed with
NuPAGE 4×LDS sample buffer (ThermoFisher Sci., catalog no. NP0007) along with NuPAGE Sample Reducing Agent (ThermoFisher Sci., catalog no. NP0004) and run on 4-12% Bis-Tris NuPAGE gels (ThermoFisher Sci.) with NuPAGE MOPS SDS running buffer (ThermoFisher Sci., catalog no. NP000102). Gels were transferred onto 0.22 μm PVDF in Towbin buffer (0.2 M Glycine, 25 mM Tris Base) containing 20% MeOH for 2 h under constant voltage (30V), the membrane blocked with 5% non-fat dry milk (NFDM)-TBST (20 mM Tris-HCL pH 7.4, 150 mM NaCl, 0.1% Tween-20) and probed with antibodies diluted in 1% NFDM-TBST overnight at 4° C. For ATR and ATM western blots, samples were processed as above except DTT (50 mM, Cell Signaling, catalog no. 7016) was used as the reducing agent and samples were run on NuPAGE Novex 3-8% Tris-acetate gels (ThermoFisher Sci.) with NuPAGE Tris-acetate SDS running buffer (ThermoFisher Sci., catalog no. LA0041). Gels were transferred under constant current (7.5 mA/cm2) for 24 h at 4° C. with Towbin buffer (0.2M Glycine, 25 mM Tris base) containing 0.1% SDS for ATR blotting or 0.05% SDS plus 20% MeOH for ATM blotting onto PVDF (0.45 μm), the membranes were then allowed to dry at RT, reactivated with MeOH, blocked in 5% NFDM-TBST containing phosphatase inhibitors (Roche, PhoSTOP tablets) and incubated overnight at 4° C. the specified antibody. Secondary antibody detection was performed by incubating blots with Pierce Goat anti-rabbit Poly-HRP (ThermoFisher Sci., catalog no. 32260) or Pierce Goat anti-mouse Poly-HRP (ThermoFisher Sci., catalog no. 32230) at 1:5000 diluted in 5% NFDM-TBST. Blots were developed with chemiluminescent substrate (Pierce ECL Western Blotting Substrate, catalog no. 32209) and imaged with a GE ImageQuant LAS4000 instrument. For re-probing, membranes were stripped with 6M guanidine hydrochloride, 0.2% NP-40, 0.1M PME, 20 mM Tris-HCL pH 7.4 (2×5′ RT followed by 4×3′ washes with TBST). - For partitioning of RIPA soluble and insoluble fractions, cells were plated and infected as described above and cells were lysed 30 min on ice with RIPA buffer (150 mM NaCl, 1% NP40, 0.1% SDS, 50 mM Tris-HCL pH 7.4). Cells were scraped into 1.5 mL Eppendorf tubes and centrifuged at 13,500 rpm for 15 min at 4° C. and the supernatant collected. The RIPA insoluble pellet was washed 3× with RIPA buffer and re-suspended in
NuPAGE 4×LDS sample buffer diluted to 1× with water. β-mercaptoethanol (OME) was added to both the RIPA-soluble and insoluble fractions at a final concentration of 12.5% and samples run on 4-12% Bis-tris gels with MOPS SDS running buffer as described above. For re-probing, membranes were stripped with 6M guanidine hydrochloride, 0.2% NP-40, 0.1 M PME, 20 mM Tris-HCL pH 7.4 (2×5′ RT followed by 4×3′ washes with TBST). - Immunofluorescence and Microscopy: U2OS cells were plated onto coverslips at 75,000 cells per well of 24-well plates and the following day infected at an MOI=10 for the indicated times.
- Initial immunofluorescence experiments with paraformaldehyde-fixed cells found that rabbit phospho-specific antibodies bound non-specifically to a juxtanuclear domain associated with the microtubule-organizing center (MTOC) (see Results). Thereafter, cells were processed for immunofluorescence in one of two ways that incorporated an Fc receptor blocking step: (1) cells were fractionated in situ by pre-extraction following previously published procedures; briefly, cells were incubated in Cytoskeleton Buffer (CB; 100 mM PIPES, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA) for 5 min on ice followed by incubation in Cytoskeleton Stripping Buffer (CSK; 10 mM Tri-HCL pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1% Tween-40, 1% Tween-20, 0.5% sodium deoxycholate) for 5 min on ice. Cells were then washed 3× with PBS and fixed with Streck fixative (150 mM 2-bromo-2-nitro-1,3-propanediol, 108 mM diazolidinyl urea, 10 mM sodium citrate, 50 mM EDTA) for 30 min at RT, washed with PBS, and permeabilized with 0.5% Triton X-100 in 100 mM Tris-HCL pH 7.4 plus 50 mM EDTA for 15 min at RT. Cells were then incubated sequentially with Fc Receptor Blocker (Innovex Biosciences, catalog no. NB309) for 30 min at RT followed by blocking buffer (5% goat serum, 0.1% NP-40, 20 mM Tris-HCL pH 7.4, 150 mM NaCl) for 30 min at RT. (2) In some cases cells were fixed in 3.7% paraformaldehyde in PBS for 5 min at RT followed by blocking with Fc Receptor Blocker and blocking buffer as above.
- Cells were processed for IF as described above. All immunofluorescence was conducted using a Nikon Eclipse E600 microscope with epifluorescence, and photographed with a Qimaging Exi Aqua Monochrome Digital camera.
- Proximity Ligation Assay (PLA): Experiments were conducted utilizing the Duolink In Situ Orange Kit Mouse/Rabbit (Sigma, catalog no. DU092102) according to the manufacturer's recommendations with some modification. Briefly, U2OS cells were plated onto coverslips at 100,000 cells per well of 24-well plates and incubated overnight in a 37° C. humidified incubator. The following day, cells were infected with 17syn+ at MOI=10 as follows: virus was adsorbed, cells were washed with PBS after 1 h, and the infection allowed to proceed for 3 h post-adsorption. Cells were fixed and processed as described previously for immunofluorescence (IF). Following permeabilization and blocking, cells were incubated with primary antibodies (same antibodies and dilutions as described for IF) for 1 h at RT, washed 3×5′ with PBS containing 1% BSA and 0.1% NP-40 (WDB) and incubated with the diluted PLA probes (diluted in WDB) per manufacturer's recommendation for 1 h at 37° C. Cells were washed 2×5′ with Wash Buffer A (from kit) and Detection was performed by incubating cells with the Ligation reaction mix for 30′ at 37° C. Cells were washed 2×2′ with Wash Buffer A and Amplification was performed by incubating cells with Polymerase reaction mix for 100 min at 37° C. Cells were washed 2×10′ with Wash Buffer B (from kit) and 1×10′ with 0.01× Wash Buffer B. Coverslips were mounted onto slides with ProLong Gold mounting media containing DAPI. PLA analysis of amplification events was carried out with the aid of Nikon's NIS-Elements basic research (BR3.2) software interfaced with a Nikon Eclipse E600 microscope using edge detection and object count dialog options.
- U2OS cells infected with HSV-1 (17+ strain, MOI=10) were initially examined by Western blotting (
FIG. 1 ) and by immunofluorescence using phospho-specific antibodies (see, e.g.,FIG. 2 ). The Western blots examined a 6 h. time course of infection. Total ATM, ATR and Chk1 levels, detected with pan-specific antibodies, did not change over the course of the experiments (FIGS. 1 , panels A and B). U2OS cells infected with HSV-1 (17+, MOI=10) showed a single immunoreactive band, reacting with the phospho-specific Chk1 antibody, migrating at 56 kDa and first appearing at 3 h.p.i. (FIG. 1 , panel A). All subsequent time points continued to show robust Chk1 phosphorylation. Infection of Vero cells under identical conditions produced identical results (FIG. 1 , panel A). ATM and ATR activation was also detected following infection. pATR levels were increased by 3 h.p.i., while pATM levels were found to be increased by 0 h.p.i., at the time of removal of HSV-1 inoculum (FIG. 1 , panel B). - In early experiments infected cells exhibited strong pATR and pChk1 fluorescence at 3 h.p.i. that was primarily concentrated in juxtanuclear domains (
FIG. 2 , panels A-H). We suspected that this finding was an artifact for several reasons. Earlier time points such as at 2 h.p.i. showed a similar result and therefore were not in agreement with Western blot time course (FIG. 9 , panels A-D). The perinuclear localization of pChk1 and pATR was within the microtubule organizing center (MTOC) and disrupted by colchicine (FIG. 9 ). The MTOC is also the site of formation of the human cytomegalovirus (CMV) “assembly compartment,” which was previously shown to especially bind rabbit IgG antibodies(62) due to the presence of CMV encoded Fc receptor-like protein(63) causing spurious results. - We therefore optimized our immunofluorescence protocol to include an Fc receptor blocking step and, in some cases, a modification of a widely used procedure for studying DDR dynamics by in situ fractionation followed by preservation with Streck's fixative(64). When applied to a time course of HSV-1 infected cells, the results faithfully reproduced the kinetics of ATR and Chk1 activation seen in Western blots (
FIG. 7 ). Both pChk1 (FIG. 2 , panels I-L & M-P) and pATR (FIG. 2 , panels Q-T) were activated and localized to the nucleus. HSV-1 replication centers were well established by 4 h.p.i., and foci of both pChk1 (FIG. 2 , panels I-L & M-P) and pATR (FIG. 2 , panels Q-T) and were found associated mainly with the periphery of these structures within the nucleus. The pChk1 fluorescence was found primarily in discreet nuclear puncta (seeFIG. 2 , panels L and P), while the pATR fluorescence was both punctate and diffuse (FIG. 2 , panels Q-T). The in situ fractionation procedure had the expected effect of reducing total nuclear labeling of pATR and pChk1 with extracted cells, while preserving punctate foci associated with the periphery of replication centers. For example, compare unextracted cells (FIG. 2 , panels I-L; and L-box) to extracted cells (FIG. 2 , panels M-T; and P-box). The foci surviving the in situ extraction procedure represent insoluble, chromatin-associated DDR complexes. - Colocalization of pATR and pChk1 with ICP4 and ICP0 suggested that these proteins may be exist together within a complex. This idea was tested using a Proximity Ligation Assay (PLA), which allows localization of the interaction of native protein pairs within a maximum distance of approximately 30 nM (32). PLA was initially used to explore the interaction of pATR with ICP4 and ICP0 in U2OS cells at 3 h.p.i. In both cases significant, bright signals were detected throughout the cytoplasm with some interaction foci also detected within the nuclei (
FIG. 3 , panel A). PLA was negative for interaction between pATR and either ICP8 or ICP27 (FIG. 3 , panel A). PLA conducted for the individual proteins were all negative, as were all PLA conducted following mock infection. PLA was next conducted in an identical fashion for pChk1. These tests resulted in nearly identical results as pATR except that the total number and brightness of PLA signals were lower (FIG. 3 , panel A). PLA for individual proteins and mock-infected samples were again negative (FIG. 3 , panel A). The PLA signal when detected for either ICP4 or ICP0 was distributed widely in the cell, but more prominent in the cytoplasm. The results showed agreement with the cell fractionation results that ICP4 and ICP0, but not ICP8, are found in the cytoplasm following infection (FIG. 5 , panel C). - The interaction of pATR and pChk1 with tubulin was tested next. Both activated enzymes gave strong positive PLA signals for tubulin interaction, while tubulin alone was negative (
FIG. 3 , panel B). Again, as for interactions detected for ICP4 and ICP0, the PLA amplification events were distributed primarily throughout the cytoplasm. Together these results indicate that both pATR and pChk1 are forming complexes with both ICP4 and ICP0, and these complexes are found in close association with microtubules. - Co-localization of pChk1 and pATR with Lamin A/B (
FIG. 5 , panel A) revealed significant activation of both proteins within the nucleus. In addition, significant pATR and pChk1 immuno-labelling occurred within the cytoplasm following HSV-1 infection compared to mock infected cells or cells in which ATR and Chk1 are activated by HU (FIG. 5 , panel A). Co-localization of pATR and pChk1 with ICP4 showed significant nuclear accumulation of these proteins where they appear to associate with replication centers, often on the periphery (FIG. 5 , panel B). Both pATR and pChk1 were also often are seen to co-localize with ICP4 within the cytoplasm (FIG. 5 , panel B). ICP0 also co-localized with ICP0 (data not shown). To confirm the cytoplasmic distribution of proteins we fractionated mock infected cells, as well as cells infected for 6 h. with 17+(MOI=10) and subjected the fractions to Western blotting (FIG. 5 , panel C). The results showed that cytoplasmic and nuclear fractions were cleanly separated with nuclear lamins and tubulin separating into the appropriate fractions. Most pChk1 separated with the nuclear fraction, but a significant amount of pChk1 was also detected in the cytoplasmic fraction of infected cells, but not mock-infected cells. In agreement with their immunofluorescence localization, a similar result was obtained for ICP4 and ICP0, but not ICP8, which was only detected in the nuclear fraction (FIG. 5 , panel C). - The specific ATR kinase VE-822 was next used to examine ATR/Chk1 activation (
FIG. 6 ). Cells receiving vehicle (0.1% DMSO) or ATR inhibitor (10 μM) were infected with HSV-1 (17+, MOI=10) and examined by Western blotting. VE-822 blocked ATR activation as observed by immunofluorescence (FIG. 6 , panel A), while Chk1 activation was also blocked as observed in Western blots (FIG. 6 , panel B). Interestingly, this series of experiments also showed that ATR inhibition by VE-822 blocked expression of ICP4 (FIG. 6 , Panel A) and ICP8 (data not shown) suggesting ATR kinase activity is required for viral fitness and viral DNA replication. The production of HSV-1 genomes following infection (MOI=0.1) of normal fibroblasts and fibroblasts derived from a Seckel syndrome patient was therefore examined. Seckel fibroblasts carry an ATR hypomorphic mutation resulting in impaired ATR function(28). HSV-1 replication was depressed in the ATR-deficient cells relative to the normal patient fibroblasts throughout the 48 h. time course (FIG. 6 , panel C). - Inhibition of protein synthesis with cycloheximide completely blocked ATR activation, while the viral polymerase inhibitor PAA partially suppressed ATR activation (
FIG. 8 ). These results suggested that the incoming viral inoculum was not responsible for ATR activation, and that viral DNA synthesis, while not required for ATR activation, may contribute to amplification ATR activation. We next asked a whether pharmacological inhibition of ATR or Chk1 kinase has antiviral effects upon HSV-1 replication. U2OS cells infected with 17+HSV-1 (MOI=0.1) were treated with one of four chemically distinct ATR inhibitors (VE-822, VE-821, AZD-6738, and AZ20), or 2 unique Chk1 inhibitors (Chir124 and PF477736), or inhibitors of ATM, Chk2, or DNA-PK (FIG. 4 ). Following the treatment infected cells were harvested to conduct viral titer assays and for Q-PCR to quantify HSV-1 genome copies. All ATR and Chk1 inhibitors, as well as the positive control aphidicolin that was expected to inhibit both viral and cell DNA replication (34) were determined to significantly inhibit viral titers (P=<0.01) (FIG. 4 , panels A&B). Inhibition of ATM, Chk2, and DNA-PK, on the other hand, modestly suppressed viral titers but not significantly (FIG. 4 , panels A&B). The measurement of viral genome copies, measured by Q-PCR, reflected and confirmed the viral titer results (FIG. 4 , panel C). - ICP0, ICP4, and ICP27 are IE phosphoproteins with the greatest effects upon HSV-1 gene expression and growth(1, 19, 35, 36). All three proteins have consensus Chk1 phosphorylation sites but no ATR sites. Interestingly, ICP8, an IE ssDNA binding protein that organizes the earliest stages of HSV-1 replication(37-39), has 3 ATR consensus sites and one Chk1 site. One ATR site exists within the C-
terminal 60 amino acid region that is required for ICP8 filament assembly and cooperative ssDNA binding(40, 41), immediately adjacent to a short sequence apparently required for ICP8 self-interactions(42). Numerous other HSV-1 proteins with central roles in viral DNA replication also possess multiple ATR and Chk1 consensus sites. - We show here using a variety of evidence that both ATR and Chk1 are rapidly activated following HSV-1 infection. Both ATR and Chk1 are rapidly phosphorylated following infection and pharmacological inhibition of ATR, but not ATM, blocks Chk1 phosphorylation, blocks formation of viral replication centers, and has a negative impact upon viral replication. We can only speculate why the previous Western blotting studies did not detect HSV-1-dependent Chk1 phosphorylation. Previous studies of ATR and Chk1 localization during HSV-1 infection utilized pan-specific antibodies to examine nuclear localization. We observe little alteration in localization of the ATR or Chk1 protein pool during infection using pan-specific antibodies, but see dramatic changes in localization of phosphorylated proteins with phospho-specific antibodies. These results indicate that the activated ATR and Chk1 moieties make up a relatively small portion of their respective protein pools.
- Viral DNA replication is required for activation of the ATR pathway following infection. Incoming viral genomes at the earliest stages of HSV-1 infection are linear DNAs with ends, nicks, and gaps that might be expected of to activate DDR pathways (43-45). For this reason we tested whether Vero cells activate ATR following infection with the replication-incompetent KD6 mutant. No evidence of Chk1 activation was noted in Vero cells although Chk1 was clearly activated following KD6 infection of permissive Vero cell line K5, and activation in these cells was blocked by the protein synthesis inhibitor cycloheximide. These results indicate that ICP4-dependent viral DNA replication, not the inoculum or the incoming viral genomes, is required to activate the ATR pathway.
- Both pATR and pChk1 were found to interact by PLA in close proximity with both ICP4 and ICP0 predominantly in the cytoplasm. While it cannot at present be ruled out that these interactions represent individual protein-protein associations, we believe the simplest explanation is that the four proteins are interacting with each other within a large, multiprotein complex. The interaction of ICP4 and ICP0 has long been recognized as important for activation of E and L gene expression. ICP0 was first identified based upon its ability to cooperate with ICP4 to promote viral mRNA synthesis (50, 51). Studies of the ability of ICP0-viruses to replicate at low versus high MOIs led to the concept that ICP0 inactivates a repressor of HSV gene expression (52-54). Other studies have shown that the two proteins are able to physically interact (55, 56).
- ATR and Chk1 are activated shortly after infection of multiple cell lines by HSV-1
strains 17+, KOS, McKrae, or McIntyre. The pathway appears to be activated by events of early gene expression. pATR and pChk1 are found in the nucleus within viral replication centers or on their periphery. Both pATR and pChk1 are also found in the cytoplasm during early stages of infection where they directly interact with ICP4 and ICP0. The specific ATR inhibitor VE-822 blocks activation of both ATR and Chk1 during infection. It also blocks maturation of replication centers during infection by blocking expression of both ICP4 and ICP8. Viral replication and production is significantly attenuated by treatment with multiple, chemically-distinct inhibitors of ATR and Chk1, but not inhibitors of ATM or Chk2. HSV-1 replication is also impaired in Seckel patient fibroblasts that are hypomorphic ATR. Together these findings demonstrate that HSV-1 activates pATR and pChk1 during infection, and that the activated kinases significantly contribute to HSV-1 replication fitness during early stages of infection. - Significant precedence exists for the cytoplasmic localization and function of activated ATR and Chk1. ATR regulates hundreds of down-stream targets, including anti-apoptotic mitochondrial elements, and its distribution in the cytoplasm following DNA damage is well documented (65). Likewise, Chk1 has nuclear export sequences and is mobilized to control cytoplasmic targets following DNA damage (66). Precedence also exists for exploitation of these DDR elements in the cytoplasm by viruses. Vaccinia, a poxvirus that replicates exclusively in the cytoplasm, activates cytoplasmic ATR, ATM, and DNA-PK, and utilizes ATR and Chk1 to promote viral genome replication (67, 68). We show that activated ATR and Chk1 appear in the cytoplasm at early stages of HSV-1 infection where they associate with ICP4 and ICP0. To the best of our knowledge, this is the first report of the cytoplasmic localization and association of activated ATR and Chk1 with ICP4 and ICP0 during HSV-1 infection. Cell fractionation, immunofluorescence co-localization, and PLA data all support this novel finding. We are at present unsure of what role this cytoplasmic association plays in the early stages of HSV-1 infection, but our data clearly show that ATR and Chk1 kinase activities are playing important roles in viral replication fitness.
- Incoming viral genomes at the earliest stages of HSV-1 infection are linear DNAs with ends, nicks, and gaps that might be expected of to activate DDR pathways (43-45). However, the complete suppression of ATR and Chk1 activation by cycloheximide indicates that new protein synthesis is required for ATR activation, and suggests that incoming viral genomes are not the cause of activation. Since the ATR pathway is also activated at early times during acute infection in the presence of PAA, a viral polymerase inhibitor, we hypothesize that early gene expression rather than viral DNA replication is an important initial event resulting in ATR activation. The partial suppression of ATR activation by PAA suggests that viral DNA replication may contribute to the amplification of the ATR signaling cascade.
- Activated ATR and Chk1 are found within the nucleus associated with the periphery of developing viral replication centers after 3 h. of HSV-1 infection. Pharmacological inhibition of ATR dramatically halts viral replication center growth and maturation. The data clearly demonstrate that ATR and Chk1 are robustly activated, and that ATR and Chk1 kinase activities are required for early HSV-1 fitness and replication. But the data are inconsistent with previous reports that concluded ATR is not activated during HSV-1 infection (17, 22), and that ATR is purposely inactivated by HSV-1 infection (23, 24). To the best of our knowledge, pATR or pChk1 localization by immunological techniques using phospho-specific antibodies were not pursued in these studies. Previous reports of ATR inactivation by HSV-1 also rested heavily upon the observation that HSV-1 infection blocks phosphorylation of the nuclear ATR target RPA(24). Perhaps one function of the association of ICP4 and ICP0 with activated ATR and Chk1 that we report here is to redirect their kinase activity away from cellular targets to viral targets that promote viral DNA replication. Whether this notion eventually proves true or not, our data strongly attests to the need at least for re-evaluation of the hypothesis that HSV-1 inactivates ATR.
- Multiple ATR and Chk1 inhibitors show potent antiviral effects against HSV-1 when used at concentrations that are reported to significantly inhibit their target protein and spare closely related kinases such as ATM and Chk2. These findings show that ATR and Chk1 kinase activities are utilized by HSV-1 to promote important aspects of viral gene expression and replication. Consistent with this is the observation that ATR inhibition: 1) inhibits expression of early genes (such as ICP4 and ICP8); 2) blocks the maturation of viral nuclear replication centers; and 3) suppresses viral growth as measured by Q-PCR or and plaque assay. While the mechanism by which ATR pathway activation enhances HSV infection is currently not clear, we hypothesize it is through down-stream effects on viral and/or host processes. Perhaps ICP4 and ICP0 act to re-direct ATR and Chk1 phosphorylation away from host targets to HSV replication proteins. It should will be useful to identify those targets of ATR and Chk1 phosphorylation that are required to maintain early viral gene expression, replication, and fitness. Importantly, the understanding that ATR and Chk1 are activated by HSV-1 to promote viral fitness will enable future studies designed to understand this important process and to perhaps design new therapeutic approaches.
-
- 1. Roizman B & Knipe D M (2001) Herpes Simplex Viruses and Their Replication. Fields Virology, eds Knipe D M & Howley P M (Lippencott Williams & Wilkins, Philadelphia), 4th Ed Vol 2, pp 2399-2457.
- 2. Weller S K & Coen D M (2012) Herpes Simplex Viruses: Mechanisms of DNA Replication. Cold Spring Harbor Perspectives in Biology 4(9).
- 3. Weitzman M D, Lilley C E, & Chaurushiya M S (2010) Genomes in Conflict: Maintaining Genome Integrity During Virus Infection. Annual Review of Microbiology, Vol 64, 2010, Annual Review of Microbiology, eds Gottesman S & Harwood C S), Vol 64, pp 61-81.
- 4. Turnell A S & Grand R J (2012) DNA viruses and the cellular DNA-damage response. J Gen Virol 93(Pt 10):2076-2097.
- 5. Luftig M (2014) Viruses and the DNA Damage Response: Activation and Antagonism. Annual Review of Virology 1:20.
- 6. Harper J W & Elledge S J (2007) The DNA damage response: ten years after. Mol Cell 28(5):739-745.
- 7. Stracker T H, Usui T, & Petrini J H (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8(9):1047-1054.
- 8. Marechal A & Zou L (2013) DNA Damage Sensing by the ATM and ATR Kinases. Cold Spring Harbor Perspectives in Biology 5(9):17.
- 9. Brown E J & Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14(4):397-402.
- 10. Brown E J & Baltimore D (2003) Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 17(5):615-628.
- 11. Cortez D, Guntuku S, Qin J, & Elledge S J (2001) ATR and ATRIP: Partners in checkpoint signaling. Science 294(5547):1713-1716.
- 12. Wang H Y, Wang H C, Powell S N, Iliakis G, & Wang Y (2004) ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 64(19):7139-7143.
- 13. You Z, et al. (2009) CTiP Links DNA Double-Strand Break Sensing to Resection. Mol Cell 36(6):954-969.
- 14. Tomimatsu N, et al. (2012) Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. DNA Repair (Amst) 11(4):441-448.
- 15. Peng G, et al. (2012) Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Res 72(11):2802-2813.
- 16. Smith S & Weller S K (2015) HSV-I and the cellular DNA damage response. Future Virol 10(4):383-397.
- 17. Lees-Miller S P, et al. (1996) Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes
simplex virus type 1 transactivator ICP0. J Virol 70(11):7471-7477. - 18. Parkinson J, Lees-Miller S P, & Everett R D (1999) Herpes
simplex virus type 1 immediate-early protein Vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol 73(1):650-657. - 19. Boutell C & Everett R D (2013) Regulation of alphaherpesvirus infections by the ICP0 family of proteins. Journal of General Virology 94:465-481.
- 20. Lilley C E, Carson C T, Muotri A R, Gage F H, & Weitzman M D (2005) DNA repair proteins affect the lifecycle of
herpes simplex virus 1. Proc Natl Acad Sci USA 102(16):5844-5849. - 21. Shirata N, et al. (2005) Activation of ataxia telangiectasia-mutated DNA damage checkpoint signal transduction elicited by herpes simplex virus infection. Journal of Biological Chemistry 280(34):30336-30341.
- 22. Wilkinson D E & Weller S K (2004) Recruitment of cellular recombination and repair proteins to sites of herpes
simplex virus type 1 DNA replication is dependent on the composition of viral proteins within prereplicative sites and correlates with the induction of the DNA damage response. J Virol 78(9):4783-4796. - 23. Lilley C E, et al. (2010) A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. Embo Journal 29(5):943-955.
- 24. Lo Piano A, Martinez-Jimenez M I, Zecchi L, & Ayora S (2011) Recombination-dependent concatemeric viral DNA replication. Virus Res 160(1-2):1-14.
- 25. Mohni K N, Dee A R, Smith S, Schumacher A J, & Weller S K (2013) Efficient
Herpes Simplex Virus 1 Replication Requires Cellular ATR Pathway Proteins. J Virol 87(1):531-542. - 26. Wilkinson D E & Weller S K (2006) Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection. J Cell Sci 119(13):2695-2703.
- 27. Wilkinson D E & Weller S K (2005) Inhibition of the herpes
simplex virus type 1 DNA polymerase induces hyperphosphorylation of replication protein a and its accumulation at S-phase-specific sites of DNA damage during infection. J Virol 79(11):7162-7171. - 28. Mohni K N, Smith S, Dee A R, Schumacher A J, & Weller S K (2013) Herpes
Simplex Virus Type 1 Single Strand DNA Binding Protein and Helicase/Primase Complex Disable Cellular ATR Signaling. PLoS Pathog 9(10). - 29. Mohni K N, Livingston C M, Cortez D, & Weller S K (2010) ATR and ATRIP Are Recruited to Herpes
Simplex Virus Type 1 Replication Compartments Even though ATR Signaling Is Disabled. J Virol 84(23):12152-12164. - 30. Botting C, Lu X, & Triezenberg S J (2016) H2AX phosphorylation and DNA damage kinase activity are dispensable for herpes simplex virus replication. Virol J 13:11.
- 31. Johnston J A, Ward C L, & Kopito R R (1998) Aggresomes: A cellular response to misfolded proteins. Journal of Cell Biology 143(7):1883-1898.
- 32.
Soderberg 0, et al. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature Methods 3(12):995-1000. - 33. Dobson A T, Margolis T P, Sedarati F, Stevens J G, & Feldman L T (1990) A LATENT, NONPATHOGENIC HSV-1-DERIVED VECTOR STABLY EXPRESSES BETA-GALACTOSIDASE IN MOUSE NEURONS. Neuron 5(3):353-360.
- 34. Larsson A, Wraak M, & Oberg B (1983) EFFECT OF APHIDICOLIN ON DNA-SYNTHESIS IN HSV-1 INFECTED AND UNINFECTED VERO CELLS. Antiviral Res 3(2):87-91.
- 35. Deluca N A, McCarthy A M, & Schaffer P A (1985) ISOLATION AND CHARACTERIZATION OF DELETION MUTANTS OF HERPES-SIMPLEX VIRUS TYPE-1 IN THE GENE ENCODING IMMEDIATE-EARLY REGULATORY PROTEIN-ICP4. J Virol 56(2):558-570.
- 36. Roizman B, Gu H D, & Mandel G (2005) The first 30 minutes in the life of a virus—unREST in the nucleus. Cell Cycle 4(8):1019-1021.
- 37. Kops A D & Knipe D M (1988) FORMATION OF DNA-REPLICATION STRUCTURES IN HERPES-VIRUS INFECTED-CELLS REQUIRES A VIRAL-DNA BINDING-PROTEIN. Cell 55(5):857-868.
- 38. Bush M, et al. (1991) CORRECT INTRANUCLEAR LOCALIZATION OF HERPES-SIMPLEX VIRUS-DNA POLYMERASE REQUIRES THE VIRAL ICP8 DNA-BINDING PROTEIN. J Virol 65(3):1082-1089.
- 39. McNamee E E, Taylor T J, & Knipe D M (2000) A dominant-negative herpesvirus protein inhibits intranuclear targeting of viral proteins: Effects on DNA replication and late gene expression. J Virol 74(21):10122-10131.
- 40. Mapelli M, Muhleisen M, Persico G, van der Zandt H, & Tucker P A (2000) The 60-residue C-terminal region of the single-stranded DNA binding protein of herpes
simplex virus type 1 is required for cooperative DNA binding. J Virol 74(19):8812-8822. - 41. Mapelli M, Panjikar S, & Tucker P A (2005) The crystal structure of the
herpes simplex virus 1 ssDNA-binding protein suggests the structural basis for flexible, cooperative single-stranded DNA binding. Journal of Biological Chemistry 280(4):2990-2997. - 42. Darwish A S, Grady L M, Bai P, & Weller S K (2016) ICP8 Filament Formation Is Essential for Replication Compartment Formation during Herpes Simplex Virus Infection. J Virol 90(5):2561-2570.
- 43. Hyman R W, Oakes J E, & Kudler L (1977) INVITRO REPAIR OF PREEXISTING NICKS AND GAPS IN HERPES-SIMPLEX VIRUS-DNA. Virology 76(1):286-294.
- 44. Wilkie N M (1973) SYNTHESIS AND SUBSTRUCTURE OF HERPESVIRUS DNA—DISTRIBUTION OF ALKALI-LABILE SINGLE-STRAND INTERRUPTIONS IN HSV-1 DNA. Journal of General Virology 21(DEC):453-467.
- 45. Smith S, Reuven N, Mohni K N, Schumacher A J, & Weller S K (2014) Structure of the
Herpes Simplex Virus 1 Genome: Manipulation of Nicks and Gaps Can Abrogate Infectivity and Alter the Cellular DNA Damage Response. J Virol 88(17):10146-10156. - 46. Wileman T (2007) Aggresomes and pericentriolar sites of virus assembly: Cellular defense or viral design? Annu Rev Microbiol, Annual Review of Microbiology, (Annual Reviews, Palo Alto), Vol 61, pp 149-167.
- 47. Wileman T (2006) Aggresomes and autophagy generate sites for virus replication.
- Science 312(5775):875-878.
- 48. Nozawa N, Yamauchi Y, Ohtsuka K, Kawaguchi Y, & Nishiyama Y (2004) Formation of aggresome-like structures in herpes simplex virus type 2-infected cells and a potential role in virus assembly. Exp Cell Res 299(2):486-497.
- 49. Gaspar M & Shenk T (2006) Human cytomegalovirus inhibits a DNA damage response by mislocalizing checkpoint proteins. Proc Natl Acad Sci USA 103(8):2821-2826.
- 50. Gelman I H & Silverstein S (1986) COORDINATE REGULATION OF HERPES-SIMPLEX VIRUS GENE-EXPRESSION IS MEDIATED BY THE FUNCTIONAL INTERACTION OF 2 IMMEDIATE EARLY GENE-PRODUCTS. J Mol Biol 191(3):395-409.
- 51. Everett R D (1984) TRANS ACTIVATION OF TRANSCRIPTION BY HERPES-VIRUS PRODUCTS—REQUIREMENT FOR 2 HSV-1 IMMEDIATE-EARLY POLYPEPTIDES FOR MAXIMUM ACTIVITY. Embo Journal 3(13):3135-3141.
- 52. Sacks W R & Schaffer P A (1987) DELETION MUTANTS IN THE GENE ENCODING THE HERPES-SIMPLEX VIRUS TYPE-1 IMMEDIATE-EARLY PROTEIN ICP0 EXHIBIT IMPAIRED GROWTH IN CELL-CULTURE. J Virol 61(3):829-839.
- 53. Everett R D (1989) CONSTRUCTION AND CHARACTERIZATION OF HERPES-SIMPLEX VIRUS TYPE-1 MUTANTS WITH DEFINED LESIONS IN IMMEDIATE EARLY GENE-1. Journal of General Virology 70:1185-1202.
- 54. Preston C M (2000) Repression of viral transcription during herpes simplex virus latency.
- Journal of General Virology 81:1-19.
- 55. Yao F & Schaffer P A (1994) PHYSICAL INTERACTION BETWEEN THE HERPES-SIMPLEX VIRUS TYPE-1 IMMEDIATE-EARLY REGULATORY PROTEINS ICP0 AND ICP4. J Virol 68(12):8158-8168.
- 56. Liu M Y, et al. (2010) ICP0 Antagonizes ICP4-Dependent Silencing of the Herpes Simplex Virus ICP0 Gene. PLoS One 5(1):16.
- 57. Roizman B, Knipe D M, & Knipe D M Whitley R J (20012007) Herpes Simplex Viruses and Their Replication. Fields Virology, eds Knipe D M & Howley P M (Lippencott Williams & Wilkins, Philadelphia), 4th 5th Ed Vol 2, pp 2399-24572501-2601.
- Brown E J & Baltimore D (2003) Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 17(5):615-628.
- 58. Stracker T H, Usui T, & Petrini J H (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8(9):1047-1054.
- 59. Edwards T G, Helmus M J, Koeller K, Bashkin J K, & Fisher C (2013) Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. J Virol 87(7):3979-3989.
- 60. Tran R K, Lieu P T, Aguilar S, Wagner E K, & Bloom D C (2002) Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes
simplex virus type 1 in mice. J Virol 76(5):2199-2205. - 61. O'Driscoll M, Ruiz-Perez V L, Woods C G, Jeggo P A, & Goodship J A (2003) A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33(4):497-501.
- 62. Alwine J C (2012) The Human Cytomegalovirus Assembly Compartment: A Masterpiece of Viral Manipulation of Cellular Processes That Facilitates Assembly and Egress. PLoS Pathog 8(9):4.
- 63. Murayama T, Natsuumesakai S, Shimokawa K, & Furukawa T (1986) FC RECEPTOR(S) INDUCED BY HUMAN CYTOMEGALOVIRUS BIND DIFFERENTIALLY WITH HUMAN IMMUNOGLOBULIN-G SUBCLASSES. Journal of General Virology 67:1475-1478.
- 64. Mirzoeva O K & Petrini J H J (2003) DNA replication-dependent nuclear dynamics of the Mre11 complex. Molecular Cancer Research 1(3):207-218.
- 65. Hilton B A, et al. (2015) ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1. Mol Cell 60(1):35-46.
- 66. Wang J N, Han X Z, Feng X J, Wang Z H, & Zhang Y W (2012) Coupling Cellular Localization and Function of Checkpoint Kinase 1 (Chk1) in Checkpoints and Cell Viability. Journal of Biological Chemistry 287(30):25501-25509.
- 67. Ferguson B J, Mansur D S, Peters N E, Ren H, & Smith G L (2012) DNA-PK is a DNA sensor for IRF-3-dependent innate immunity.
Elife 1. - 68. Postigo A, Ramsden A E, Howell M, & Way M (2017) Cytoplasmic ATR Activation Promotes Vaccinia Virus Genome Replication. Cell Reports 19(5):1022-1032.
- The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an element, an embodiment herein includes that element or embodiment as any single element or embodiment or in combination with any other element, embodiments or portions thereof.
- The disclosures of each and every patent, patent application and publication cited herein are hereby incorporated herein by reference in their entirety.
- Although the invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of the invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The claims are intended to be construed to include all such embodiments and equivalent variations.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/343,285 US20230414608A1 (en) | 2016-09-12 | 2023-06-28 | Use of atr and chk1 inhibitor compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662393166P | 2016-09-12 | 2016-09-12 | |
PCT/US2017/051176 WO2018049400A1 (en) | 2016-09-12 | 2017-09-12 | Use of atr and chk1 inhibitor compounds |
US201916332211A | 2019-03-11 | 2019-03-11 | |
US18/343,285 US20230414608A1 (en) | 2016-09-12 | 2023-06-28 | Use of atr and chk1 inhibitor compounds |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/332,211 Division US11730734B2 (en) | 2016-09-12 | 2017-09-12 | Use of ATR and Chk1 inhibitor compounds |
PCT/US2017/051176 Division WO2018049400A1 (en) | 2016-09-12 | 2017-09-12 | Use of atr and chk1 inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414608A1 true US20230414608A1 (en) | 2023-12-28 |
Family
ID=61562294
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/332,211 Active 2040-11-25 US11730734B2 (en) | 2016-09-12 | 2017-09-12 | Use of ATR and Chk1 inhibitor compounds |
US18/343,285 Pending US20230414608A1 (en) | 2016-09-12 | 2023-06-28 | Use of atr and chk1 inhibitor compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/332,211 Active 2040-11-25 US11730734B2 (en) | 2016-09-12 | 2017-09-12 | Use of ATR and Chk1 inhibitor compounds |
Country Status (2)
Country | Link |
---|---|
US (2) | US11730734B2 (en) |
WO (1) | WO2018049400A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202140474A (en) * | 2020-01-17 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused heteroaryl derivatives, preparation method and medical use thereof |
US20230190736A1 (en) * | 2020-04-10 | 2023-06-22 | The Regents Of The University Of California | Small molecule therapeutics for the treatment of viral infections |
JP2023530001A (en) * | 2020-06-18 | 2023-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds for the treatment of viral infections |
US20240174977A1 (en) * | 2021-04-28 | 2024-05-30 | Shandong University | Methods for improving early embryo development |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10106619B2 (en) * | 2006-10-04 | 2018-10-23 | La Jolla Institute For Allergy And Immunology | Virus vaccination and treatment methods with OX40 agonist compositions |
ES2921576T3 (en) * | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compounds useful as ATR kinase inhibitors |
AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
WO2015057461A2 (en) * | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use |
WO2018118586A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Antiviral/endogenous combination therapy |
US20230053688A1 (en) * | 2020-01-10 | 2023-02-23 | Cornell University | Methods to alter latency in ebv+ malignancies |
-
2017
- 2017-09-12 WO PCT/US2017/051176 patent/WO2018049400A1/en active Application Filing
- 2017-09-12 US US16/332,211 patent/US11730734B2/en active Active
-
2023
- 2023-06-28 US US18/343,285 patent/US20230414608A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190269682A1 (en) | 2019-09-05 |
WO2018049400A1 (en) | 2018-03-15 |
US11730734B2 (en) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230414608A1 (en) | Use of atr and chk1 inhibitor compounds | |
Edwards et al. | The ATM and Rad3-related (ATR) protein kinase pathway is activated by herpes simplex virus 1 and required for efficient viral replication | |
US20120046246A1 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
AU2008229483A1 (en) | Kinase protein binding inhibitors | |
US8569356B2 (en) | Cyclin dependent kinase inhibitors | |
US20170240570A1 (en) | Novel small molecule anticancer agents | |
EP3341362B1 (en) | Compositions for app-selective bace inhibition and uses therfor | |
WO2010027458A2 (en) | Pdk inhibitor compounds and methods of use thereof | |
Dohme et al. | Broad-spectrum antiviral diazadispiroalkane core molecules block attachment and cell-to-cell spread of herpesviruses | |
US20120195911A1 (en) | Method of treatment of cancer patients | |
US11512073B2 (en) | Benzimidazole derivatives, pharmaceutical composition comprising the same, and use thereof | |
US20170071952A1 (en) | Methods and compositions for treating viral infections | |
Suryawanshi et al. | Putative targeting by BX795 causes decrease in protein kinase C protein levels and inhibition of HSV1 infection | |
US20030060457A1 (en) | Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins | |
US8314150B2 (en) | Kinase protein binding inhibitors | |
EP3235511A1 (en) | Sulphonamide compounds for use in the treatment of hhv-8-associated diseases | |
US20030049602A1 (en) | Inhibitors of microbial gene expression replication and pathogenesis | |
US11058699B2 (en) | Method and compositions for inhibition of double stranded DNA viruses | |
Kalu | Pharmacologically-induced cellular stress and herpesvirus replication | |
WO2023229685A2 (en) | Broad-spectrum inhibitors of cytomegalovirus | |
US20150051245A1 (en) | Kinase protein binding inhibitors | |
Leach | Role of emerin and protein kinase C in herpes simplex nuclear egress | |
Gillen | Proteomic and functional analysis of ORF45 interactome during the lytic cycle of Kaposi's sarcoma-associated herpesvirus | |
CA2754834A1 (en) | Kinase protein binding inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FISHER, CHRISTOPHER;BLOOM, DAVID C.;EDWARDS, TERRI G.;REEL/FRAME:065046/0545 Effective date: 20190625 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |